{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T19:13:37Z","timestamp":1679080417095},"reference-count":178,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.addr.2021.01.001","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T02:52:17Z","timestamp":1610074337000},"page":"71-82","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"title":["Recombinant protein vaccines, a proven approach against coronavirus pandemics"],"prefix":"10.1016","volume":"170","author":[{"given":"Jeroen","family":"Pollet","sequence":"first","affiliation":[]},{"given":"Wen-Hsiang","family":"Chen","sequence":"additional","affiliation":[]},{"given":"Ulrich","family":"Strych","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2021.01.001_bb0005","series-title":"Coronavirus: Sputnik V vaccine rushed out to wary Russians","author":"Rainsford","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0010","article-title":"China drugmaker fact-checks claim that its leading COVID vaccine is 97% effective","author":"McGregor","year":"2020","journal-title":"Fortune"},{"key":"10.1016\/j.addr.2021.01.001_bb0015","series-title":"As U.K. Begins Vaccinations, A Glimpse of Life After Covid","author":"Mueller","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0020","series-title":"Canada Authorizes Use Of Pfizer COVID-19 Vaccine","author":"Dwyer","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0025","series-title":"DRAFT Landscape of COVID-19 Candidate Vaccines","author":"WHO","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0030","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.01.001_bb0035","series-title":"A Study Looking at the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults at Risk for SARS-CoV-2","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0040","series-title":"Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With\/Without Matrix-M Adjuvant","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0045","article-title":"Sanofi-GSK covid-19 vaccine is set back by lab mistake","author":"Dalton","year":"2020","journal-title":"Wall Street J."},{"key":"10.1016\/j.addr.2021.01.001_bb0050","series-title":"SCB-2019 as COVID-19 Vaccine","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0055","article-title":"S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates","author":"Liang","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0060","series-title":"A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0065","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-77077-z","article-title":"Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19","volume":"10","author":"Kuo","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2021.01.001_bb0070","series-title":"Monovalent Recombinant COVID19 Vaccine (COVAX19)","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0075","series-title":"Vaxine and Medytox \u2013 COVAX-19\u00ae","author":"Genengnews","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0080","series-title":"A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0085","series-title":"Biological E\u2019s Novel Covid-19 Vaccine of SARS-CoV-2 for Protection Against Covid-19 Disease","author":"CTRI","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0090","article-title":"SARS-CoV-2 RBD219-N1C1: a yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice","author":"Pollet","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0095","article-title":"Cloning, expression and biophysical characterization of a yeast-expressed recombinant SARS-CoV-2 receptor binding domain COVID-19 vaccine candidate","author":"Chen","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0100","author":"RPCEC","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0105","series-title":"Soberana is Cuba\u2019s, The First Candidate Vaccine Against COVID-19 in Latin America and the Caribbean, Granma - The OFFICIAL VOICE OF THE COMMUNIST PARTY OF CUBA CENTRAL COMMITTEE","author":"Morales","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0110","series-title":"KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0115","series-title":"Clinical Study of Recombinant Novel Coronavirus Vaccine","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0120","series-title":"A Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial of the Effectiveness and Safety of Inoculation of Recombinant New Coronavirus Vaccine (CHO cells) in the Prevention of COVID-19 in People 18 Years and Older","author":"CHICTR","year":"2020"},{"issue":"7830","key":"10.1016\/j.addr.2021.01.001_bb0125","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-020-2599-8","article-title":"A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity","volume":"586","author":"Yang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.01.001_bb0130","series-title":"Recombinant COVID-19 Vaccine (Sf9 cells) Phase II Clinical Trial","author":"CHICTR","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0135","series-title":"Randomized Double Blind, Placebo Controlled Phase I Trial for Anti Novel Coronavirus Pneumonia (COVID-19) Recombinant Vaccine (Sf9)","author":"CHICTR","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0140","series-title":"COVAXX \u2013 UB-612","author":"Genetic_Engineering&Biotechnology_News","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0145","series-title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0150","series-title":"Study of the Safety, Reactogenicity and Immunogenicity of \u201cEpiVacCorona\u201d Vaccine for the Prevention of COVID-19 (EpiVacCorona)","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0155","series-title":"Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults (pVAC)","author":"Clinicaltrials_gov","year":"2020"},{"issue":"1","key":"10.1016\/j.addr.2021.01.001_bb0160","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41590-020-00808-x","article-title":"SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition","volume":"22","author":"Nelde","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0165","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","article-title":"Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.addr.2021.01.001_bb0170","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00512-20","article-title":"Laboratory diagnosis of COVID-19: current issues and challenges","volume":"58","author":"Tang","year":"2020","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.addr.2021.01.001_bb0175","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3201\/eid2607.200841","article-title":"Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients","volume":"26","author":"Okba","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.addr.2021.01.001_bb0180","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/cid\/ciaa310","article-title":"Profiling early humoral response to diagnose novel coronavirus disease (COVID-19)","volume":"71","author":"Guo","year":"2020","journal-title":"Clin. Infect. Dis.: Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.addr.2021.01.001_bb0185","doi-asserted-by":"crossref","first-page":"6337","DOI":"10.4049\/jimmunol.181.9.6337","article-title":"Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV","volume":"181","author":"Yasui","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0190","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41423-020-0400-4","article-title":"Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine","volume":"17","author":"Tai","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"6483","key":"10.1016\/j.addr.2021.01.001_bb0195","first-page":"1260","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0200","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.addr.2021.01.001_bb0205","first-page":"92","article-title":"The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin","volume":"5","author":"Xia","year":"2020","journal-title":"Signal Trans. Targ. Therapy"},{"key":"10.1016\/j.addr.2021.01.001_bb0210","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12967-020-02392-y","article-title":"SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines","volume":"18","author":"Salvatori","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.addr.2021.01.001_bb0215","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/2965cfae-b77d-4014-8b7b-236e01a35492","article-title":"Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus","volume":"7","author":"Tseng","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2021.01.001_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030237","article-title":"Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants","volume":"3","author":"ter Meulen","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.addr.2021.01.001_bb0225","series-title":"WIPO","article-title":"Chimeric molecules and uses thereof","author":"Chappell","year":"2018"},{"key":"10.1016\/j.addr.2021.01.001_bb0230","series-title":"Molecular Clamp Stabilised Spike Protein For Protection Against SARS- CoV-2","author":"Watterson","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0235","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.01.001_bb0240","doi-asserted-by":"crossref","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","article-title":"Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen","volume":"114","author":"Pallesen","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2021.01.001_bb0245","article-title":"Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19","author":"Kuo","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0250","doi-asserted-by":"crossref","first-page":"8953","DOI":"10.1038\/s41598-017-09518-1","article-title":"Improvement of pharmacokinetic profile of TRAIL via trimer-tag enhances its antitumor activity in vivo","volume":"7","author":"Liu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2021.01.001_bb0255","article-title":"Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C\/B' HIV-1 candidate vaccine","volume":"5","author":"Vasan","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2021.01.001_bb0260","doi-asserted-by":"crossref","first-page":"10324","DOI":"10.1128\/JVI.00480-13","article-title":"An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody","volume":"87","author":"Petrovsky","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.01.001_bb0265","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1128\/CVI.00019-14","article-title":"Advax-adjuvanted recombinant protective antigen provides protection against inhalational anthrax that is further enhanced by addition of murabutide adjuvant","volume":"21","author":"Feinen","year":"2014","journal-title":"Clin. Vaccine Immunol.: CVI"},{"key":"10.1016\/j.addr.2021.01.001_bb0270","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1016\/j.vaccine.2014.09.034","article-title":"Immunogenicity and safety of Advax, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study","volume":"32","author":"Gordon","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0275","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1016\/j.vaccine.2015.09.030","article-title":"Advax, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety","volume":"33","author":"Petrovsky","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0280","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ebiom.2016.11.015","article-title":"Advax, a delta inulin microparticle, potentiates in-built adjuvant property of co-administered vaccines","volume":"15","author":"Hayashi","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.addr.2021.01.001_bb0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2017.1279765","article-title":"Panblok-H1+advax H1N1\/2009pdm vaccine: insights into rapid development of a delta inulin adjuvanted recombinant pandemic influenza vaccine","volume":"13","author":"Honda-Okubo","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0290","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jconrel.2018.09.006","article-title":"Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge","volume":"288","author":"Tomar","year":"2018","journal-title":"J. Control. Rel.: Off. J. Control. Rel. Soc."},{"key":"10.1016\/j.addr.2021.01.001_bb0295","article-title":"Development of unique Australian COVID-19 vaccine halted","author":"Norville","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.01.001_bb0300","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","article-title":"A Universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS","volume":"182","author":"Dai","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.addr.2021.01.001_bb0305","series-title":"COVAXX Announces First Multitope Peptide-Based Vaccine to Enter Human Trials","author":"PipelineReviews","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0310","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41577-020-0323-4","article-title":"COVID-19 vaccine design: the Janus face of immune enhancement","volume":"20","author":"Hotez","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0315","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/136419","article-title":"Comparative evaluation of recombinant protein production in different biofactories: the green perspective","volume":"2014","author":"Merlin","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.addr.2021.01.001_bb0320","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3390\/pr7080476","article-title":"Recombinant proteins for industrial versus pharmaceutical purposes: a review of process and pricing","volume":"7","author":"Puetz","year":"2019","journal-title":"Processes"},{"key":"10.1016\/j.addr.2021.01.001_bb0325","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3389\/fmicb.2014.00172","article-title":"Recombinant protein expression in Escherichia coli: advances and challenges","volume":"5","author":"Rosano","year":"2014","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.addr.2021.01.001_bb0330","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4155\/pbp.14.8","article-title":"Biopharmaceutical protein production by Saccharomyces cerevisiae: current state and future prospects","volume":"2","author":"Huang","year":"2014","journal-title":"Pharm. Bioprocess."},{"key":"10.1016\/j.addr.2021.01.001_bb0335","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/07853890.2017.1407035","article-title":"Understanding modern-day vaccines: what you need to know","volume":"50","author":"Vetter","year":"2018","journal-title":"Ann. Med."},{"key":"10.1016\/j.addr.2021.01.001_bb0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0950268806007096","article-title":"The Lyme vaccine: a cautionary tale","volume":"135","author":"Nigrovic","year":"2007","journal-title":"Epidemiol. Infect."},{"key":"10.1016\/j.addr.2021.01.001_bb0345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113294","article-title":"Design and development of a novel vaccine for protection against Lyme borreliosis","volume":"9","author":"Comstedt","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2021.01.001_bb0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184357","article-title":"The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes","volume":"12","author":"Comstedt","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2021.01.001_bb0355","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1080\/00325481.2016.1203238","article-title":"Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba(R))","volume":"128","author":"Gandhi","year":"2016","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.addr.2021.01.001_bb0360","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40259-015-0139-0","article-title":"Bivalent rLP2086 vaccine (Trumenba((R))): a review in active immunization against invasive meningococcal group b disease in individuals aged 10-25 years","volume":"29","author":"Shirley","year":"2015","journal-title":"BioDrugs: Clin. Immunother. Biopharm. Gene Therapy"},{"key":"10.1016\/j.addr.2021.01.001_bb0365","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/14760584.2017.1308828","article-title":"Emerging experience with meningococcal serogroup B protein vaccines","volume":"16","author":"Toneatto","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2021.01.001_bb0370","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/B978-0-12-420070-8.00012-X","article-title":"Protein expression-yeast","volume":"536","author":"Nielsen","year":"2014","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.addr.2021.01.001_bb0375","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/298347a0","article-title":"Synthesis and assembly of hepatitis B virus surface antigen particles in yeast","volume":"298","author":"Valenzuela","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.01.001_bb0380","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1590\/S1679-45082013000400027","article-title":"Vaccination against human papillomavirus","volume":"11","author":"Mello","year":"2013","journal-title":"Einstein"},{"key":"10.1016\/j.addr.2021.01.001_bb0385","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nprot.2008.213","article-title":"Engineering complex-type N-glycosylation in Pichia pastoris using GlycoSwitch technology","volume":"4","author":"Jacobs","year":"2009","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.addr.2021.01.001_bb0390","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","article-title":"Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike","volume":"584","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.01.001_bb0395","series-title":"Coronavirus|U.S.-Based Baylor College of Medicine Ties Up with India\u2019s Biological E for COVID-19 Vaccine","author":"PTI","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0400","series-title":"Biological E. Limited Starts Phase I\/II Clinical Trial of its COVID-19 Vaccine Candidate","author":"Dynavax","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0405","doi-asserted-by":"crossref","first-page":"648","DOI":"10.4161\/hv.27464","article-title":"Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate","volume":"10","author":"Chen","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0410","article-title":"Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with alum induces protective immunity and reduces immune enhancement","author":"Chen","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0415","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3389\/fbioe.2019.00420","article-title":"Recent developments in bioprocessing of recombinant proteins: expression hosts and process development","volume":"7","author":"Tripathi","year":"2019","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.addr.2021.01.001_bb0420","first-page":"20","article-title":"Recombinant glycoprotein E of varicella zoster virus contains glycan-peptide motifs that modulate B cell epitopes into discrete immunological signatures","author":"Norden","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2021.01.001_bb0425","first-page":"2156","article-title":"Production of human beta interferon in insect cells infected with a baculovirus expression vector","volume":"3","author":"Smith","year":"1983","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.addr.2021.01.001_bb0430","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nbt1095","article-title":"Baculovirus as versatile vectors for protein expression in insect and mammalian cells","volume":"23","author":"Kost","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2021.01.001_bb0435","first-page":"47","article-title":"Trends in the development of baculovirus expression vectors","volume":"6","author":"Luckow","year":"1988","journal-title":"Bio\/Technology"},{"key":"10.1016\/j.addr.2021.01.001_bb0440","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/bit.260361108","article-title":"High-level recombinant protein production in bioreactors using the baculovirus-insect cell expression system","volume":"36","author":"Caron","year":"1990","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.addr.2021.01.001_bb0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/btpr.1842","article-title":"Protein production using the baculovirus-insect cell expression system","volume":"30","author":"Contreras-Gomez","year":"2013","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.addr.2021.01.001_bb0450","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.2174\/138945007782151360","article-title":"Protein N-glycosylation in the baculovirus-insect cell system","volume":"8","author":"Shi","year":"2007","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.addr.2021.01.001_bb0455","series-title":"BAT Working on Potential COVID-19 Vaccine through US Bio-tech Subsidiary","author":"BAT","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0460","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1104\/pp.124.3.927","article-title":"Production of recombinant proteins in tobacco guttation fluid","volume":"124","author":"Komarnytsky","year":"2000","journal-title":"Plant Physiol."},{"key":"10.1016\/j.addr.2021.01.001_bb0465","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.4161\/21645515.2014.980199","article-title":"New tools for NTD vaccines: A case study of quality control assays for product development of the human hookworm vaccine Na-APR-1M74","volume":"11","author":"Pearson","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0470","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1080\/21645515.2015.1036207","article-title":"Expression, purification, and characterization of the Necator americanus aspartic protease-1 (Na-APR-1 (M74)) antigen, a component of the bivalent human hookworm vaccine","volume":"11","author":"Seid","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0475","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.biotechadv.2009.11.008","article-title":"Tobacco, a highly efficient green bioreactor for production of therapeutic proteins","volume":"28","author":"Tremblay","year":"2010","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.addr.2021.01.001_bb0480","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/4216060","article-title":"A brief reminder of systems of production and chromatography-based recovery of recombinant protein biopharmaceuticals","volume":"2019","author":"Owczarek","year":"2019","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.addr.2021.01.001_bb0485","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1387-2656(07)13004-0","article-title":"Preparation of recombinant vaccines","volume":"13","author":"Soler","year":"2007","journal-title":"Biotechnol. Annu. Rev."},{"key":"10.1016\/j.addr.2021.01.001_bb0490","series-title":"Development and Licensure of Vaccines to Prevent COVID-19: Guidance for Industry","author":"FDA","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0495","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13223-018-0305-2","article-title":"Unraveling the enigma: elucidating the relationship between the physicochemical properties of aluminium-based adjuvants and their immunological mechanisms of action","volume":"14","author":"Shardlow","year":"2018","journal-title":"Allergy Asthma Clin. Immunol.: Off. J. Can. Soc. Allergy Clin. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0500","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/21645515.2014.1004026","article-title":"Advances in aluminum hydroxide-based adjuvant research and its mechanism","volume":"11","author":"He","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0505","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1128\/JVI.02980-14","article-title":"Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology","volume":"89","author":"Honda-Okubo","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.01.001_bb0510","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41577-020-0358-6","article-title":"COVID-19 vaccines: neutralizing antibodies and the alum advantage","volume":"20","author":"Hotez","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0515","series-title":"Developing a Low-Cost and Accessible COVID-19 Vaccine for Global Health","author":"Hotez","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0520","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1080\/21645515.2018.1495301","article-title":"Immunology and efficacy of MF59-adjuvanted vaccines","volume":"14","author":"Ko","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0525","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1586\/14760584.6.5.699","article-title":"MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection","volume":"6","author":"O'Hagan","year":"2007","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2021.01.001_bb0530","series-title":"Adjuvanted Flu Vaccine","author":"CDC","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0535","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1002\/1521-4141(2001010)31:10<2910::AID-IMMU2910>3.0.CO;2-3","article-title":"Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis","volume":"31","author":"Dupuis","year":"2001","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0540","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.4049\/jimmunol.153.9.4029","article-title":"Systemic cytokine profiles in BALB\/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants","volume":"153","author":"Valensi","year":"1994","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0545","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/erv.11.23","article-title":"MF59 adjuvant: the best insurance against influenza strain diversity","volume":"10","author":"O'Hagan","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2021.01.001_bb0550","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00011-020-01377-3","article-title":"SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus","volume":"69","author":"Oberemok","year":"2020","journal-title":"Inflamm. Res.: Off. J. Eur. Histam. Res. Soc. \u2026 [et al.]"},{"key":"10.1016\/j.addr.2021.01.001_bb0555","series-title":"Vaccine Adjuvants: Methods and Protocols","first-page":"15","article-title":"Development of the CpG adjuvant 1018: A case study","author":"Campbell","year":"2016"},{"key":"10.1016\/j.addr.2021.01.001_bb0560","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1016\/j.vaccine.2019.04.048","article-title":"Safety of AS03-adjuvanted influenza vaccines: a review of the evidence","volume":"37","author":"Cohet","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0565","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1080\/21645515.2016.1168954","article-title":"Evaluation of potential immunogenicity differences between Pandemrix\u2122 and Arepanrix\u2122","volume":"12","author":"Canelle","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0570","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3389\/fimmu.2017.01760","article-title":"AS03- and MF59-adjuvanted influenza vaccines in children","volume":"8","author":"Wilkins","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0575","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12026-018-8991-x","article-title":"Matrix-M adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice","volume":"66","author":"Magnusson","year":"2018","journal-title":"Immunol. Res."},{"key":"10.1016\/j.addr.2021.01.001_bb0580","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.vaccine.2013.01.039","article-title":"Immune enhancing properties of the novel matrix-M adjuvant leads to potentiated immune responses to an influenza vaccine in mice","volume":"31","author":"Magnusson","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0585","first-page":"49","article-title":"Induction of virus-specific immunity by iscoms","volume":"92","author":"Osterhaus","year":"1998","journal-title":"Dev. Biol. Stand."},{"key":"10.1016\/j.addr.2021.01.001_bb0590","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1016\/j.vaccine.2011.08.042","article-title":"Evaluation of a virosomal H5N1 vaccine formulated with matrix M adjuvant in a phase I clinical trial","volume":"29","author":"Cox","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0595","series-title":"Study of Parenterally Administrated Adjuvanted Seasonal Influenza Vaccine in Healthy Elderly Volunteers","author":"Clinicaltrials_gov","year":"2011"},{"key":"10.1016\/j.addr.2021.01.001_bb0600","series-title":"A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1\u2122 Adjuvant","author":"Clinicaltrials_gov","year":"2014"},{"key":"10.1016\/j.addr.2021.01.001_bb0605","series-title":"Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1\u2122 Adjuvants In Clinically-Stable Older Adults","author":"Clinicaltrials_gov","year":"2017"},{"key":"10.1016\/j.addr.2021.01.001_bb0610","series-title":"A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, Administered With and Without Matrix-M1","author":"Clinicaltrials_gov","year":"2019"},{"key":"10.1016\/j.addr.2021.01.001_bb0615","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jaci.2019.03.035","article-title":"Randomized controlled trial demonstrating the benefits of delta inulin adjuvanted immunotherapy in patients with bee venom allergy","volume":"144","author":"Heddle","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0620","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","article-title":"Immunological considerations for COVID-19 vaccine strategies","volume":"20","author":"Jeyanathan","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0625","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.micinf.2020.04.005","article-title":"The potential role of Th17 immune responses in coronavirus immunopathology and vaccine-induced immune enhancement","volume":"22","author":"Hotez","year":"2020","journal-title":"Microbes Infect."},{"key":"10.1016\/j.addr.2021.01.001_bb0630","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.4049\/jimmunol.0800531","article-title":"Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth Onchocerca volvulus, can directly bind and activate antigen-presenting cells","volume":"182","author":"He","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0635","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.0141-9838.2004.00685.x","article-title":"Ov-ASP-1, the Onchocerca volvulus homologue of the activation associated secreted protein family is immunostimulatory and can induce protective anti-larval immunity","volume":"26","author":"MacDonald","year":"2004","journal-title":"Parasite Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0640","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1016\/j.vaccine.2008.07.028","article-title":"Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccines","volume":"26","author":"Xiao","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0645","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1743-422X-7-9","article-title":"An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses","volume":"7","author":"Zhao","year":"2010","journal-title":"Virol. J."},{"key":"10.1016\/j.addr.2021.01.001_bb0650","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00215-18","article-title":"The mucosal vaccine adjuvant LT(R192G\/L211A) or dmLT","volume":"3","author":"Clements","year":"2018","journal-title":"mSphere"},{"key":"10.1016\/j.addr.2021.01.001_bb0655","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.vaccine.2015.02.069","article-title":"The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model","volume":"33","author":"Norton","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0660","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bbi.2020.05.057","article-title":"The role of IgA in COVID-19","volume":"87","author":"Chao","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.addr.2021.01.001_bb0665","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1586\/14760584.2015.1081067","article-title":"Effect of vaccine administration modality on immunogenicity and efficacy","volume":"14","author":"Zhang","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2021.01.001_bb0670","first-page":"2145","article-title":"Intradermal injection, as opposed to subcutaneous injection, enhances immunogenicity and suppresses tumorigenicity of tumor cells","volume":"63","author":"Bonnotte","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2021.01.001_bb0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102743","article-title":"Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development","volume":"55","author":"Kim","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.addr.2021.01.001_bb0680","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.ijbiomac.2020.05.239","article-title":"A recombinant Lactobacillus plantarum strain expressing the spike protein of SARS-CoV-2","volume":"160","author":"Wang","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.addr.2021.01.001_bb0685","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S1473-3099(15)00266-2","article-title":"High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial","volume":"15","author":"Liebowitz","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.addr.2021.01.001_bb0690","series-title":"Vaxart's oral COVID-19 Tablet Vaccine to Enter Clinical Trials","author":"Arthur","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0695","series-title":"Merck Looks to Lower Barriers to COVID-19 Vaccination with Oral Approach","author":"Eaton","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0700","series-title":"Chinese Covid-19 Vaccine Candidate Becomes First Nasal Spray to Start Clinical Trial","author":"Simin","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0705","series-title":"Nasal Spray Vaccine for Covid-19","author":"ClinicalTrialsArena","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0710","series-title":"Single-Dose Intranasal COVID-19 Vaccine","author":"Altimmune","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0715","series-title":"FluGen, Bharat Biotech to develop CoroFlu, a coronavirus vaccine","author":"University_of_Wisconsin, UW\u2013Madison","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0720","series-title":"Fundamentals and Applications of Controlled Release Drug Delivery","author":"Siepmann","year":"2012"},{"key":"10.1016\/j.addr.2021.01.001_bb0725","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8303648","article-title":"Alternative methods of vaccine delivery: an overview of edible and intradermal vaccines","volume":"2019","author":"Criscuolo","year":"2019","journal-title":"J Immunol Res"},{"key":"10.1016\/j.addr.2021.01.001_bb0730","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1016\/j.vaccine.2012.05.011","article-title":"Survey of the prevalence of immunization non-compliance due to needle fears in children and adults","volume":"30","author":"Taddio","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0735","doi-asserted-by":"crossref","first-page":"7214","DOI":"10.1016\/j.vaccine.2006.06.043","article-title":"Physiochemical and functional characterization of antigen proteins eluted from aluminum hydroxide adjuvant","volume":"24","author":"Hutcheon","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0740","doi-asserted-by":"crossref","first-page":"13406","DOI":"10.1074\/jbc.M500687200","article-title":"Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens","volume":"280","author":"Jones","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2021.01.001_bb0745","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijpharm.2005.04.037","article-title":"Preparation of coated nanoparticles for a new mucosal vaccine delivery system","volume":"299","author":"Borges","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2021.01.001_bb0750","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41541-020-0190-9","article-title":"New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes","volume":"5","author":"Amacker","year":"2020","journal-title":"NPJ Vaccines"},{"issue":"Suppl. 1","key":"10.1016\/j.addr.2021.01.001_bb0755","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.vaccine.2005.04.026","article-title":"The virosome concept for influenza vaccines","volume":"23","author":"Huckriede","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0760","series-title":"Mymetics Starts Second Preclinical Study for Virosome-based Covid-19 Vaccine","author":"Kempers","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0765","series-title":"A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0770","series-title":"Novavax Initiates Efficacy Trial of COVID-19 Vaccine in South Africa","author":"Novavax","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0775","series-title":"COVID-19 Tracker: Warp Speed Chief Eyes Timeline for Pfizer, Moderna, AZ Shot Data; FDA can Reveal Safety info If Vaccine Makers Don't, Official Says, Fierce_Pharma","author":"Sagonowsky","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0780","series-title":"Dynavax Announces First Participants Dosed in Phase 1 Clinical Trial Evaluating Clover Biopharmaceuticals\u2019 COVID-19 S-Trimer Vaccine Candidate with CpG 1018 Adjuvant","author":"Biospace","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0785","series-title":"Clover Announces Formation of a Global Scientific Advisory Board for its COVID-19 Vaccine Program","author":"Clover_Biopharma","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0790","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.01.001_bb0795","article-title":"Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment","author":"Malladi","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2021.01.001_bb0800","article-title":"A vaccine displaying a trimeric influenza-a ha stem protein on capsid-like particles elicits potent and long-lasting protection in mice","volume":"8","author":"Thrane","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.addr.2021.01.001_bb0805","series-title":"COVID-19 cVLP Vaccine Demonstrated as Effective in Mice","author":"de Jongh","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0810","series-title":"ExpreS2ion Announces Successful Manufacturing of the cVLP COVID-19 Vaccine and Further Positive Updates","author":"Frandsen","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0815","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s12026-013-8468-x","article-title":"Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer and infectious diseases","volume":"57","author":"Strbo","year":"2013","journal-title":"Immunol. Res."},{"key":"10.1016\/j.addr.2021.01.001_bb0820","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jcpa.2014.01.004","article-title":"The pathology and pathogenesis of experimental severe acute respiratory syndrome and influenza in animal models","volume":"151","author":"van den Brand","year":"2014","journal-title":"J. Comp. Pathol."},{"key":"10.1016\/j.addr.2021.01.001_bb0825","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1128\/CVI.00455-14","article-title":"Multiple low-dose challenges in a rhesus macaque AIDS vaccine trial result in an evolving host response that affects protective outcome","volume":"21","author":"Selinger","year":"2014","journal-title":"Clin. Vaccine Immunol.: CVI"},{"key":"10.1016\/j.addr.2021.01.001_bb0830","article-title":"Induction of SARS-CoV-2 protein S-specific CD8+T cells in the lungs of gp96-Ig-S vaccinated mice","author":"Fisher","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0835","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01083-20","article-title":"COVID-19 vaccines: \u201cWarp Speed\u201d needs mind melds, not warped minds","volume":"94","author":"Moore","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.01.001_bb0840","series-title":"Correlates and Disparities of COVID-19 Vaccine Hesitancy","author":"Callaghan","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0845","article-title":"Protein-based Covid-19 vaccines could overshadow rivals","author":"King","year":"2020","journal-title":"Chem. World"},{"key":"10.1016\/j.addr.2021.01.001_bb0850","series-title":"Pfizer, Moderna's Coronavirus Shot Rollouts Could Freeze Up, Experts Say, Citing Cold-storage Needs","author":"Blankenship","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0855","article-title":"Safety and immunogenicity of heterologous and homologous two dose regimens of Ad26- and MVA-vectored ebola vaccines: a randomized, controlled phase 1 study","author":"Goldstein","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2021.01.001_bb0860","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines2030624","article-title":"Developments in viral vector-based vaccines","volume":"2","author":"Ura","year":"2014","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.addr.2021.01.001_bb0865","doi-asserted-by":"crossref","first-page":"11434","DOI":"10.1128\/JVI.78.20.11434-11438.2004","article-title":"Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors","volume":"78","author":"Casimiro","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.01.001_bb0870","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2021.01.001_bb0875","article-title":"Safety and immunogenicity of the Ad26.RSV.preF investigational vaccine coadministered with an influenza vaccine in older adults","author":"Sadoff","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2021.01.001_bb0880","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An Mrna vaccine against SARS-CoV-2 - preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.01.001_bb0885","article-title":"RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study","author":"Walsh","year":"2020","journal-title":"medRxiv: Preprint Server Health Sci."},{"key":"10.1016\/j.addr.2021.01.001_bb0890","series-title":"After Admitting Mistake, AstraZeneca Faces Difficult Questions About Its Vaccine","author":"Robbins","year":"2020"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X21000016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X21000016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T12:42:48Z","timestamp":1673440968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X21000016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":178,"alternative-id":["S0169409X21000016"],"URL":"http:\/\/dx.doi.org\/10.1016\/j.addr.2021.01.001","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":["Pharmaceutical Science"],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant protein vaccines, a proven approach against coronavirus pandemics","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2021.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}
{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T19:13:37Z","timestamp":1679080417095},"reference-count":178,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.addr.2021.01.001","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T02:52:17Z","timestamp":1610074337000},"page":"71-82","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"title":["Recombinant protein vaccines, a proven approach against coronavirus pandemics"],"prefix":"10.1016","volume":"170","author":[{"given":"Jeroen","family":"Pollet","sequence":"first","affiliation":[]},{"given":"Wen-Hsiang","family":"Chen","sequence":"additional","affiliation":[]},{"given":"Ulrich","family":"Strych","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2021.01.001_bb0005","series-title":"Coronavirus: Sputnik V vaccine rushed out to wary Russians","author":"Rainsford","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0010","article-title":"China drugmaker fact-checks claim that its leading COVID vaccine is 97% effective","author":"McGregor","year":"2020","journal-title":"Fortune"},{"key":"10.1016\/j.addr.2021.01.001_bb0015","series-title":"As U.K. Begins Vaccinations, A Glimpse of Life After Covid","author":"Mueller","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0020","series-title":"Canada Authorizes Use Of Pfizer COVID-19 Vaccine","author":"Dwyer","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0025","series-title":"DRAFT Landscape of COVID-19 Candidate Vaccines","author":"WHO","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0030","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.01.001_bb0035","series-title":"A Study Looking at the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults at Risk for SARS-CoV-2","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0040","series-title":"Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With\/Without Matrix-M Adjuvant","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0045","article-title":"Sanofi-GSK covid-19 vaccine is set back by lab mistake","author":"Dalton","year":"2020","journal-title":"Wall Street J."},{"key":"10.1016\/j.addr.2021.01.001_bb0050","series-title":"SCB-2019 as COVID-19 Vaccine","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0055","article-title":"S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates","author":"Liang","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0060","series-title":"A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0065","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-77077-z","article-title":"Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19","volume":"10","author":"Kuo","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2021.01.001_bb0070","series-title":"Monovalent Recombinant COVID19 Vaccine (COVAX19)","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0075","series-title":"Vaxine and Medytox \u2013 COVAX-19\u00ae","author":"Genengnews","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0080","series-title":"A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0085","series-title":"Biological E\u2019s Novel Covid-19 Vaccine of SARS-CoV-2 for Protection Against Covid-19 Disease","author":"CTRI","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0090","article-title":"SARS-CoV-2 RBD219-N1C1: a yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice","author":"Pollet","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0095","article-title":"Cloning, expression and biophysical characterization of a yeast-expressed recombinant SARS-CoV-2 receptor binding domain COVID-19 vaccine candidate","author":"Chen","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0100","author":"RPCEC","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0105","series-title":"Soberana is Cuba\u2019s, The First Candidate Vaccine Against COVID-19 in Latin America and the Caribbean, Granma - The OFFICIAL VOICE OF THE COMMUNIST PARTY OF CUBA CENTRAL COMMITTEE","author":"Morales","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0110","series-title":"KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0115","series-title":"Clinical Study of Recombinant Novel Coronavirus Vaccine","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0120","series-title":"A Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial of the Effectiveness and Safety of Inoculation of Recombinant New Coronavirus Vaccine (CHO cells) in the Prevention of COVID-19 in People 18 Years and Older","author":"CHICTR","year":"2020"},{"issue":"7830","key":"10.1016\/j.addr.2021.01.001_bb0125","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-020-2599-8","article-title":"A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity","volume":"586","author":"Yang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.01.001_bb0130","series-title":"Recombinant COVID-19 Vaccine (Sf9 cells) Phase II Clinical Trial","author":"CHICTR","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0135","series-title":"Randomized Double Blind, Placebo Controlled Phase I Trial for Anti Novel Coronavirus Pneumonia (COVID-19) Recombinant Vaccine (Sf9)","author":"CHICTR","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0140","series-title":"COVAXX \u2013 UB-612","author":"Genetic_Engineering&Biotechnology_News","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0145","series-title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0150","series-title":"Study of the Safety, Reactogenicity and Immunogenicity of \u201cEpiVacCorona\u201d Vaccine for the Prevention of COVID-19 (EpiVacCorona)","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0155","series-title":"Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults (pVAC)","author":"Clinicaltrials_gov","year":"2020"},{"issue":"1","key":"10.1016\/j.addr.2021.01.001_bb0160","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41590-020-00808-x","article-title":"SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition","volume":"22","author":"Nelde","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0165","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","article-title":"Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.addr.2021.01.001_bb0170","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00512-20","article-title":"Laboratory diagnosis of COVID-19: current issues and challenges","volume":"58","author":"Tang","year":"2020","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.addr.2021.01.001_bb0175","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3201\/eid2607.200841","article-title":"Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients","volume":"26","author":"Okba","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.addr.2021.01.001_bb0180","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/cid\/ciaa310","article-title":"Profiling early humoral response to diagnose novel coronavirus disease (COVID-19)","volume":"71","author":"Guo","year":"2020","journal-title":"Clin. Infect. Dis.: Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.addr.2021.01.001_bb0185","doi-asserted-by":"crossref","first-page":"6337","DOI":"10.4049\/jimmunol.181.9.6337","article-title":"Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV","volume":"181","author":"Yasui","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0190","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41423-020-0400-4","article-title":"Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine","volume":"17","author":"Tai","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"6483","key":"10.1016\/j.addr.2021.01.001_bb0195","first-page":"1260","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0200","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.addr.2021.01.001_bb0205","first-page":"92","article-title":"The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin","volume":"5","author":"Xia","year":"2020","journal-title":"Signal Trans. Targ. Therapy"},{"key":"10.1016\/j.addr.2021.01.001_bb0210","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12967-020-02392-y","article-title":"SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines","volume":"18","author":"Salvatori","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.addr.2021.01.001_bb0215","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/2965cfae-b77d-4014-8b7b-236e01a35492","article-title":"Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus","volume":"7","author":"Tseng","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2021.01.001_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030237","article-title":"Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants","volume":"3","author":"ter Meulen","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.addr.2021.01.001_bb0225","series-title":"WIPO","article-title":"Chimeric molecules and uses thereof","author":"Chappell","year":"2018"},{"key":"10.1016\/j.addr.2021.01.001_bb0230","series-title":"Molecular Clamp Stabilised Spike Protein For Protection Against SARS- CoV-2","author":"Watterson","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0235","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.01.001_bb0240","doi-asserted-by":"crossref","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","article-title":"Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen","volume":"114","author":"Pallesen","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2021.01.001_bb0245","article-title":"Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19","author":"Kuo","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0250","doi-asserted-by":"crossref","first-page":"8953","DOI":"10.1038\/s41598-017-09518-1","article-title":"Improvement of pharmacokinetic profile of TRAIL via trimer-tag enhances its antitumor activity in vivo","volume":"7","author":"Liu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2021.01.001_bb0255","article-title":"Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C\/B' HIV-1 candidate vaccine","volume":"5","author":"Vasan","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2021.01.001_bb0260","doi-asserted-by":"crossref","first-page":"10324","DOI":"10.1128\/JVI.00480-13","article-title":"An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody","volume":"87","author":"Petrovsky","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.01.001_bb0265","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1128\/CVI.00019-14","article-title":"Advax-adjuvanted recombinant protective antigen provides protection against inhalational anthrax that is further enhanced by addition of murabutide adjuvant","volume":"21","author":"Feinen","year":"2014","journal-title":"Clin. Vaccine Immunol.: CVI"},{"key":"10.1016\/j.addr.2021.01.001_bb0270","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1016\/j.vaccine.2014.09.034","article-title":"Immunogenicity and safety of Advax, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study","volume":"32","author":"Gordon","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0275","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1016\/j.vaccine.2015.09.030","article-title":"Advax, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety","volume":"33","author":"Petrovsky","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0280","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ebiom.2016.11.015","article-title":"Advax, a delta inulin microparticle, potentiates in-built adjuvant property of co-administered vaccines","volume":"15","author":"Hayashi","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.addr.2021.01.001_bb0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2017.1279765","article-title":"Panblok-H1+advax H1N1\/2009pdm vaccine: insights into rapid development of a delta inulin adjuvanted recombinant pandemic influenza vaccine","volume":"13","author":"Honda-Okubo","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0290","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jconrel.2018.09.006","article-title":"Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge","volume":"288","author":"Tomar","year":"2018","journal-title":"J. Control. Rel.: Off. J. Control. Rel. Soc."},{"key":"10.1016\/j.addr.2021.01.001_bb0295","article-title":"Development of unique Australian COVID-19 vaccine halted","author":"Norville","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.01.001_bb0300","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","article-title":"A Universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS","volume":"182","author":"Dai","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.addr.2021.01.001_bb0305","series-title":"COVAXX Announces First Multitope Peptide-Based Vaccine to Enter Human Trials","author":"PipelineReviews","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0310","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41577-020-0323-4","article-title":"COVID-19 vaccine design: the Janus face of immune enhancement","volume":"20","author":"Hotez","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0315","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/136419","article-title":"Comparative evaluation of recombinant protein production in different biofactories: the green perspective","volume":"2014","author":"Merlin","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.addr.2021.01.001_bb0320","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3390\/pr7080476","article-title":"Recombinant proteins for industrial versus pharmaceutical purposes: a review of process and pricing","volume":"7","author":"Puetz","year":"2019","journal-title":"Processes"},{"key":"10.1016\/j.addr.2021.01.001_bb0325","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3389\/fmicb.2014.00172","article-title":"Recombinant protein expression in Escherichia coli: advances and challenges","volume":"5","author":"Rosano","year":"2014","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.addr.2021.01.001_bb0330","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4155\/pbp.14.8","article-title":"Biopharmaceutical protein production by Saccharomyces cerevisiae: current state and future prospects","volume":"2","author":"Huang","year":"2014","journal-title":"Pharm. Bioprocess."},{"key":"10.1016\/j.addr.2021.01.001_bb0335","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/07853890.2017.1407035","article-title":"Understanding modern-day vaccines: what you need to know","volume":"50","author":"Vetter","year":"2018","journal-title":"Ann. Med."},{"key":"10.1016\/j.addr.2021.01.001_bb0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0950268806007096","article-title":"The Lyme vaccine: a cautionary tale","volume":"135","author":"Nigrovic","year":"2007","journal-title":"Epidemiol. Infect."},{"key":"10.1016\/j.addr.2021.01.001_bb0345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113294","article-title":"Design and development of a novel vaccine for protection against Lyme borreliosis","volume":"9","author":"Comstedt","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2021.01.001_bb0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184357","article-title":"The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes","volume":"12","author":"Comstedt","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2021.01.001_bb0355","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1080\/00325481.2016.1203238","article-title":"Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba(R))","volume":"128","author":"Gandhi","year":"2016","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.addr.2021.01.001_bb0360","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40259-015-0139-0","article-title":"Bivalent rLP2086 vaccine (Trumenba((R))): a review in active immunization against invasive meningococcal group b disease in individuals aged 10-25 years","volume":"29","author":"Shirley","year":"2015","journal-title":"BioDrugs: Clin. Immunother. Biopharm. Gene Therapy"},{"key":"10.1016\/j.addr.2021.01.001_bb0365","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/14760584.2017.1308828","article-title":"Emerging experience with meningococcal serogroup B protein vaccines","volume":"16","author":"Toneatto","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2021.01.001_bb0370","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/B978-0-12-420070-8.00012-X","article-title":"Protein expression-yeast","volume":"536","author":"Nielsen","year":"2014","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.addr.2021.01.001_bb0375","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/298347a0","article-title":"Synthesis and assembly of hepatitis B virus surface antigen particles in yeast","volume":"298","author":"Valenzuela","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.01.001_bb0380","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1590\/S1679-45082013000400027","article-title":"Vaccination against human papillomavirus","volume":"11","author":"Mello","year":"2013","journal-title":"Einstein"},{"key":"10.1016\/j.addr.2021.01.001_bb0385","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nprot.2008.213","article-title":"Engineering complex-type N-glycosylation in Pichia pastoris using GlycoSwitch technology","volume":"4","author":"Jacobs","year":"2009","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.addr.2021.01.001_bb0390","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","article-title":"Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike","volume":"584","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.01.001_bb0395","series-title":"Coronavirus|U.S.-Based Baylor College of Medicine Ties Up with India\u2019s Biological E for COVID-19 Vaccine","author":"PTI","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0400","series-title":"Biological E. Limited Starts Phase I\/II Clinical Trial of its COVID-19 Vaccine Candidate","author":"Dynavax","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0405","doi-asserted-by":"crossref","first-page":"648","DOI":"10.4161\/hv.27464","article-title":"Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate","volume":"10","author":"Chen","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0410","article-title":"Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with alum induces protective immunity and reduces immune enhancement","author":"Chen","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0415","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3389\/fbioe.2019.00420","article-title":"Recent developments in bioprocessing of recombinant proteins: expression hosts and process development","volume":"7","author":"Tripathi","year":"2019","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.addr.2021.01.001_bb0420","first-page":"20","article-title":"Recombinant glycoprotein E of varicella zoster virus contains glycan-peptide motifs that modulate B cell epitopes into discrete immunological signatures","author":"Norden","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2021.01.001_bb0425","first-page":"2156","article-title":"Production of human beta interferon in insect cells infected with a baculovirus expression vector","volume":"3","author":"Smith","year":"1983","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.addr.2021.01.001_bb0430","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nbt1095","article-title":"Baculovirus as versatile vectors for protein expression in insect and mammalian cells","volume":"23","author":"Kost","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2021.01.001_bb0435","first-page":"47","article-title":"Trends in the development of baculovirus expression vectors","volume":"6","author":"Luckow","year":"1988","journal-title":"Bio\/Technology"},{"key":"10.1016\/j.addr.2021.01.001_bb0440","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/bit.260361108","article-title":"High-level recombinant protein production in bioreactors using the baculovirus-insect cell expression system","volume":"36","author":"Caron","year":"1990","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.addr.2021.01.001_bb0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/btpr.1842","article-title":"Protein production using the baculovirus-insect cell expression system","volume":"30","author":"Contreras-Gomez","year":"2013","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.addr.2021.01.001_bb0450","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.2174\/138945007782151360","article-title":"Protein N-glycosylation in the baculovirus-insect cell system","volume":"8","author":"Shi","year":"2007","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.addr.2021.01.001_bb0455","series-title":"BAT Working on Potential COVID-19 Vaccine through US Bio-tech Subsidiary","author":"BAT","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0460","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1104\/pp.124.3.927","article-title":"Production of recombinant proteins in tobacco guttation fluid","volume":"124","author":"Komarnytsky","year":"2000","journal-title":"Plant Physiol."},{"key":"10.1016\/j.addr.2021.01.001_bb0465","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.4161\/21645515.2014.980199","article-title":"New tools for NTD vaccines: A case study of quality control assays for product development of the human hookworm vaccine Na-APR-1M74","volume":"11","author":"Pearson","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0470","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1080\/21645515.2015.1036207","article-title":"Expression, purification, and characterization of the Necator americanus aspartic protease-1 (Na-APR-1 (M74)) antigen, a component of the bivalent human hookworm vaccine","volume":"11","author":"Seid","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0475","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.biotechadv.2009.11.008","article-title":"Tobacco, a highly efficient green bioreactor for production of therapeutic proteins","volume":"28","author":"Tremblay","year":"2010","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.addr.2021.01.001_bb0480","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/4216060","article-title":"A brief reminder of systems of production and chromatography-based recovery of recombinant protein biopharmaceuticals","volume":"2019","author":"Owczarek","year":"2019","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.addr.2021.01.001_bb0485","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1387-2656(07)13004-0","article-title":"Preparation of recombinant vaccines","volume":"13","author":"Soler","year":"2007","journal-title":"Biotechnol. Annu. Rev."},{"key":"10.1016\/j.addr.2021.01.001_bb0490","series-title":"Development and Licensure of Vaccines to Prevent COVID-19: Guidance for Industry","author":"FDA","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0495","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13223-018-0305-2","article-title":"Unraveling the enigma: elucidating the relationship between the physicochemical properties of aluminium-based adjuvants and their immunological mechanisms of action","volume":"14","author":"Shardlow","year":"2018","journal-title":"Allergy Asthma Clin. Immunol.: Off. J. Can. Soc. Allergy Clin. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0500","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/21645515.2014.1004026","article-title":"Advances in aluminum hydroxide-based adjuvant research and its mechanism","volume":"11","author":"He","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0505","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1128\/JVI.02980-14","article-title":"Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology","volume":"89","author":"Honda-Okubo","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.01.001_bb0510","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41577-020-0358-6","article-title":"COVID-19 vaccines: neutralizing antibodies and the alum advantage","volume":"20","author":"Hotez","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0515","series-title":"Developing a Low-Cost and Accessible COVID-19 Vaccine for Global Health","author":"Hotez","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0520","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1080\/21645515.2018.1495301","article-title":"Immunology and efficacy of MF59-adjuvanted vaccines","volume":"14","author":"Ko","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0525","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1586\/14760584.6.5.699","article-title":"MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection","volume":"6","author":"O'Hagan","year":"2007","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2021.01.001_bb0530","series-title":"Adjuvanted Flu Vaccine","author":"CDC","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0535","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1002\/1521-4141(2001010)31:103.0.CO;2-3","article-title":"Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis","volume":"31","author":"Dupuis","year":"2001","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0540","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.4049\/jimmunol.153.9.4029","article-title":"Systemic cytokine profiles in BALB\/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants","volume":"153","author":"Valensi","year":"1994","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0545","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/erv.11.23","article-title":"MF59 adjuvant: the best insurance against influenza strain diversity","volume":"10","author":"O'Hagan","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2021.01.001_bb0550","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00011-020-01377-3","article-title":"SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus","volume":"69","author":"Oberemok","year":"2020","journal-title":"Inflamm. Res.: Off. J. Eur. Histam. Res. Soc. \u2026 [et al.]"},{"key":"10.1016\/j.addr.2021.01.001_bb0555","series-title":"Vaccine Adjuvants: Methods and Protocols","first-page":"15","article-title":"Development of the CpG adjuvant 1018: A case study","author":"Campbell","year":"2016"},{"key":"10.1016\/j.addr.2021.01.001_bb0560","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1016\/j.vaccine.2019.04.048","article-title":"Safety of AS03-adjuvanted influenza vaccines: a review of the evidence","volume":"37","author":"Cohet","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0565","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1080\/21645515.2016.1168954","article-title":"Evaluation of potential immunogenicity differences between Pandemrix\u2122 and Arepanrix\u2122","volume":"12","author":"Canelle","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0570","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3389\/fimmu.2017.01760","article-title":"AS03- and MF59-adjuvanted influenza vaccines in children","volume":"8","author":"Wilkins","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0575","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12026-018-8991-x","article-title":"Matrix-M adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice","volume":"66","author":"Magnusson","year":"2018","journal-title":"Immunol. Res."},{"key":"10.1016\/j.addr.2021.01.001_bb0580","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.vaccine.2013.01.039","article-title":"Immune enhancing properties of the novel matrix-M adjuvant leads to potentiated immune responses to an influenza vaccine in mice","volume":"31","author":"Magnusson","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0585","first-page":"49","article-title":"Induction of virus-specific immunity by iscoms","volume":"92","author":"Osterhaus","year":"1998","journal-title":"Dev. Biol. Stand."},{"key":"10.1016\/j.addr.2021.01.001_bb0590","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1016\/j.vaccine.2011.08.042","article-title":"Evaluation of a virosomal H5N1 vaccine formulated with matrix M adjuvant in a phase I clinical trial","volume":"29","author":"Cox","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0595","series-title":"Study of Parenterally Administrated Adjuvanted Seasonal Influenza Vaccine in Healthy Elderly Volunteers","author":"Clinicaltrials_gov","year":"2011"},{"key":"10.1016\/j.addr.2021.01.001_bb0600","series-title":"A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1\u2122 Adjuvant","author":"Clinicaltrials_gov","year":"2014"},{"key":"10.1016\/j.addr.2021.01.001_bb0605","series-title":"Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1\u2122 Adjuvants In Clinically-Stable Older Adults","author":"Clinicaltrials_gov","year":"2017"},{"key":"10.1016\/j.addr.2021.01.001_bb0610","series-title":"A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, Administered With and Without Matrix-M1","author":"Clinicaltrials_gov","year":"2019"},{"key":"10.1016\/j.addr.2021.01.001_bb0615","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jaci.2019.03.035","article-title":"Randomized controlled trial demonstrating the benefits of delta inulin adjuvanted immunotherapy in patients with bee venom allergy","volume":"144","author":"Heddle","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0620","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","article-title":"Immunological considerations for COVID-19 vaccine strategies","volume":"20","author":"Jeyanathan","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0625","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.micinf.2020.04.005","article-title":"The potential role of Th17 immune responses in coronavirus immunopathology and vaccine-induced immune enhancement","volume":"22","author":"Hotez","year":"2020","journal-title":"Microbes Infect."},{"key":"10.1016\/j.addr.2021.01.001_bb0630","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.4049\/jimmunol.0800531","article-title":"Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth Onchocerca volvulus, can directly bind and activate antigen-presenting cells","volume":"182","author":"He","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0635","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.0141-9838.2004.00685.x","article-title":"Ov-ASP-1, the Onchocerca volvulus homologue of the activation associated secreted protein family is immunostimulatory and can induce protective anti-larval immunity","volume":"26","author":"MacDonald","year":"2004","journal-title":"Parasite Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0640","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1016\/j.vaccine.2008.07.028","article-title":"Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccines","volume":"26","author":"Xiao","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0645","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1743-422X-7-9","article-title":"An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses","volume":"7","author":"Zhao","year":"2010","journal-title":"Virol. J."},{"key":"10.1016\/j.addr.2021.01.001_bb0650","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00215-18","article-title":"The mucosal vaccine adjuvant LT(R192G\/L211A) or dmLT","volume":"3","author":"Clements","year":"2018","journal-title":"mSphere"},{"key":"10.1016\/j.addr.2021.01.001_bb0655","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.vaccine.2015.02.069","article-title":"The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model","volume":"33","author":"Norton","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0660","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bbi.2020.05.057","article-title":"The role of IgA in COVID-19","volume":"87","author":"Chao","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.addr.2021.01.001_bb0665","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1586\/14760584.2015.1081067","article-title":"Effect of vaccine administration modality on immunogenicity and efficacy","volume":"14","author":"Zhang","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2021.01.001_bb0670","first-page":"2145","article-title":"Intradermal injection, as opposed to subcutaneous injection, enhances immunogenicity and suppresses tumorigenicity of tumor cells","volume":"63","author":"Bonnotte","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2021.01.001_bb0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102743","article-title":"Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development","volume":"55","author":"Kim","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.addr.2021.01.001_bb0680","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.ijbiomac.2020.05.239","article-title":"A recombinant Lactobacillus plantarum strain expressing the spike protein of SARS-CoV-2","volume":"160","author":"Wang","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.addr.2021.01.001_bb0685","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S1473-3099(15)00266-2","article-title":"High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial","volume":"15","author":"Liebowitz","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.addr.2021.01.001_bb0690","series-title":"Vaxart's oral COVID-19 Tablet Vaccine to Enter Clinical Trials","author":"Arthur","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0695","series-title":"Merck Looks to Lower Barriers to COVID-19 Vaccination with Oral Approach","author":"Eaton","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0700","series-title":"Chinese Covid-19 Vaccine Candidate Becomes First Nasal Spray to Start Clinical Trial","author":"Simin","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0705","series-title":"Nasal Spray Vaccine for Covid-19","author":"ClinicalTrialsArena","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0710","series-title":"Single-Dose Intranasal COVID-19 Vaccine","author":"Altimmune","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0715","series-title":"FluGen, Bharat Biotech to develop CoroFlu, a coronavirus vaccine","author":"University_of_Wisconsin, UW\u2013Madison","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0720","series-title":"Fundamentals and Applications of Controlled Release Drug Delivery","author":"Siepmann","year":"2012"},{"key":"10.1016\/j.addr.2021.01.001_bb0725","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8303648","article-title":"Alternative methods of vaccine delivery: an overview of edible and intradermal vaccines","volume":"2019","author":"Criscuolo","year":"2019","journal-title":"J Immunol Res"},{"key":"10.1016\/j.addr.2021.01.001_bb0730","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1016\/j.vaccine.2012.05.011","article-title":"Survey of the prevalence of immunization non-compliance due to needle fears in children and adults","volume":"30","author":"Taddio","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0735","doi-asserted-by":"crossref","first-page":"7214","DOI":"10.1016\/j.vaccine.2006.06.043","article-title":"Physiochemical and functional characterization of antigen proteins eluted from aluminum hydroxide adjuvant","volume":"24","author":"Hutcheon","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0740","doi-asserted-by":"crossref","first-page":"13406","DOI":"10.1074\/jbc.M500687200","article-title":"Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens","volume":"280","author":"Jones","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2021.01.001_bb0745","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijpharm.2005.04.037","article-title":"Preparation of coated nanoparticles for a new mucosal vaccine delivery system","volume":"299","author":"Borges","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2021.01.001_bb0750","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41541-020-0190-9","article-title":"New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes","volume":"5","author":"Amacker","year":"2020","journal-title":"NPJ Vaccines"},{"issue":"Suppl. 1","key":"10.1016\/j.addr.2021.01.001_bb0755","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.vaccine.2005.04.026","article-title":"The virosome concept for influenza vaccines","volume":"23","author":"Huckriede","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0760","series-title":"Mymetics Starts Second Preclinical Study for Virosome-based Covid-19 Vaccine","author":"Kempers","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0765","series-title":"A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0770","series-title":"Novavax Initiates Efficacy Trial of COVID-19 Vaccine in South Africa","author":"Novavax","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0775","series-title":"COVID-19 Tracker: Warp Speed Chief Eyes Timeline for Pfizer, Moderna, AZ Shot Data; FDA can Reveal Safety info If Vaccine Makers Don't, Official Says, Fierce_Pharma","author":"Sagonowsky","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0780","series-title":"Dynavax Announces First Participants Dosed in Phase 1 Clinical Trial Evaluating Clover Biopharmaceuticals\u2019 COVID-19 S-Trimer Vaccine Candidate with CpG 1018 Adjuvant","author":"Biospace","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0785","series-title":"Clover Announces Formation of a Global Scientific Advisory Board for its COVID-19 Vaccine Program","author":"Clover_Biopharma","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0790","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.01.001_bb0795","article-title":"Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment","author":"Malladi","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2021.01.001_bb0800","article-title":"A vaccine displaying a trimeric influenza-a ha stem protein on capsid-like particles elicits potent and long-lasting protection in mice","volume":"8","author":"Thrane","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.addr.2021.01.001_bb0805","series-title":"COVID-19 cVLP Vaccine Demonstrated as Effective in Mice","author":"de Jongh","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0810","series-title":"ExpreS2ion Announces Successful Manufacturing of the cVLP COVID-19 Vaccine and Further Positive Updates","author":"Frandsen","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0815","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s12026-013-8468-x","article-title":"Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer and infectious diseases","volume":"57","author":"Strbo","year":"2013","journal-title":"Immunol. Res."},{"key":"10.1016\/j.addr.2021.01.001_bb0820","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jcpa.2014.01.004","article-title":"The pathology and pathogenesis of experimental severe acute respiratory syndrome and influenza in animal models","volume":"151","author":"van den Brand","year":"2014","journal-title":"J. Comp. Pathol."},{"key":"10.1016\/j.addr.2021.01.001_bb0825","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1128\/CVI.00455-14","article-title":"Multiple low-dose challenges in a rhesus macaque AIDS vaccine trial result in an evolving host response that affects protective outcome","volume":"21","author":"Selinger","year":"2014","journal-title":"Clin. Vaccine Immunol.: CVI"},{"key":"10.1016\/j.addr.2021.01.001_bb0830","article-title":"Induction of SARS-CoV-2 protein S-specific CD8+T cells in the lungs of gp96-Ig-S vaccinated mice","author":"Fisher","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0835","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01083-20","article-title":"COVID-19 vaccines: \u201cWarp Speed\u201d needs mind melds, not warped minds","volume":"94","author":"Moore","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.01.001_bb0840","series-title":"Correlates and Disparities of COVID-19 Vaccine Hesitancy","author":"Callaghan","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0845","article-title":"Protein-based Covid-19 vaccines could overshadow rivals","author":"King","year":"2020","journal-title":"Chem. World"},{"key":"10.1016\/j.addr.2021.01.001_bb0850","series-title":"Pfizer, Moderna's Coronavirus Shot Rollouts Could Freeze Up, Experts Say, Citing Cold-storage Needs","author":"Blankenship","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0855","article-title":"Safety and immunogenicity of heterologous and homologous two dose regimens of Ad26- and MVA-vectored ebola vaccines: a randomized, controlled phase 1 study","author":"Goldstein","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2021.01.001_bb0860","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines2030624","article-title":"Developments in viral vector-based vaccines","volume":"2","author":"Ura","year":"2014","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.addr.2021.01.001_bb0865","doi-asserted-by":"crossref","first-page":"11434","DOI":"10.1128\/JVI.78.20.11434-11438.2004","article-title":"Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors","volume":"78","author":"Casimiro","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.01.001_bb0870","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2021.01.001_bb0875","article-title":"Safety and immunogenicity of the Ad26.RSV.preF investigational vaccine coadministered with an influenza vaccine in older adults","author":"Sadoff","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2021.01.001_bb0880","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An Mrna vaccine against SARS-CoV-2 - preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.01.001_bb0885","article-title":"RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study","author":"Walsh","year":"2020","journal-title":"medRxiv: Preprint Server Health Sci."},{"key":"10.1016\/j.addr.2021.01.001_bb0890","series-title":"After Admitting Mistake, AstraZeneca Faces Difficult Questions About Its Vaccine","author":"Robbins","year":"2020"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X21000016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X21000016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T12:42:48Z","timestamp":1673440968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X21000016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":178,"alternative-id":["S0169409X21000016"],"URL":"http:\/\/dx.doi.org\/10.1016\/j.addr.2021.01.001","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":["Pharmaceutical Science"],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant protein vaccines, a proven approach against coronavirus pandemics","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2021.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}
{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T19:13:37Z","timestamp":1679080417095},"reference-count":178,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.addr.2021.01.001","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T02:52:17Z","timestamp":1610074337000},"page":"71-82","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"title":["Recombinant protein vaccines, a proven approach against coronavirus pandemics"],"prefix":"10.1016","volume":"170","author":[{"given":"Jeroen","family":"Pollet","sequence":"first","affiliation":[]},{"given":"Wen-Hsiang","family":"Chen","sequence":"additional","affiliation":[]},{"given":"Ulrich","family":"Strych","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2021.01.001_bb0005","series-title":"Coronavirus: Sputnik V vaccine rushed out to wary Russians","author":"Rainsford","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0010","article-title":"China drugmaker fact-checks claim that its leading COVID vaccine is 97% effective","author":"McGregor","year":"2020","journal-title":"Fortune"},{"key":"10.1016\/j.addr.2021.01.001_bb0015","series-title":"As U.K. Begins Vaccinations, A Glimpse of Life After Covid","author":"Mueller","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0020","series-title":"Canada Authorizes Use Of Pfizer COVID-19 Vaccine","author":"Dwyer","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0025","series-title":"DRAFT Landscape of COVID-19 Candidate Vaccines","author":"WHO","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0030","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.01.001_bb0035","series-title":"A Study Looking at the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults at Risk for SARS-CoV-2","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0040","series-title":"Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With\/Without Matrix-M Adjuvant","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0045","article-title":"Sanofi-GSK covid-19 vaccine is set back by lab mistake","author":"Dalton","year":"2020","journal-title":"Wall Street J."},{"key":"10.1016\/j.addr.2021.01.001_bb0050","series-title":"SCB-2019 as COVID-19 Vaccine","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0055","article-title":"S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates","author":"Liang","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0060","series-title":"A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0065","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-77077-z","article-title":"Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19","volume":"10","author":"Kuo","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2021.01.001_bb0070","series-title":"Monovalent Recombinant COVID19 Vaccine (COVAX19)","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0075","series-title":"Vaxine and Medytox \u2013 COVAX-19\u00ae","author":"Genengnews","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0080","series-title":"A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0085","series-title":"Biological E\u2019s Novel Covid-19 Vaccine of SARS-CoV-2 for Protection Against Covid-19 Disease","author":"CTRI","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0090","article-title":"SARS-CoV-2 RBD219-N1C1: a yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice","author":"Pollet","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0095","article-title":"Cloning, expression and biophysical characterization of a yeast-expressed recombinant SARS-CoV-2 receptor binding domain COVID-19 vaccine candidate","author":"Chen","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0100","author":"RPCEC","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0105","series-title":"Soberana is Cuba\u2019s, The First Candidate Vaccine Against COVID-19 in Latin America and the Caribbean, Granma - The OFFICIAL VOICE OF THE COMMUNIST PARTY OF CUBA CENTRAL COMMITTEE","author":"Morales","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0110","series-title":"KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0115","series-title":"Clinical Study of Recombinant Novel Coronavirus Vaccine","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0120","series-title":"A Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial of the Effectiveness and Safety of Inoculation of Recombinant New Coronavirus Vaccine (CHO cells) in the Prevention of COVID-19 in People 18 Years and Older","author":"CHICTR","year":"2020"},{"issue":"7830","key":"10.1016\/j.addr.2021.01.001_bb0125","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-020-2599-8","article-title":"A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity","volume":"586","author":"Yang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.01.001_bb0130","series-title":"Recombinant COVID-19 Vaccine (Sf9 cells) Phase II Clinical Trial","author":"CHICTR","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0135","series-title":"Randomized Double Blind, Placebo Controlled Phase I Trial for Anti Novel Coronavirus Pneumonia (COVID-19) Recombinant Vaccine (Sf9)","author":"CHICTR","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0140","series-title":"COVAXX \u2013 UB-612","author":"Genetic_Engineering&Biotechnology_News","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0145","series-title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0150","series-title":"Study of the Safety, Reactogenicity and Immunogenicity of \u201cEpiVacCorona\u201d Vaccine for the Prevention of COVID-19 (EpiVacCorona)","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0155","series-title":"Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults (pVAC)","author":"Clinicaltrials_gov","year":"2020"},{"issue":"1","key":"10.1016\/j.addr.2021.01.001_bb0160","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41590-020-00808-x","article-title":"SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition","volume":"22","author":"Nelde","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0165","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","article-title":"Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.addr.2021.01.001_bb0170","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00512-20","article-title":"Laboratory diagnosis of COVID-19: current issues and challenges","volume":"58","author":"Tang","year":"2020","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.addr.2021.01.001_bb0175","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3201\/eid2607.200841","article-title":"Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients","volume":"26","author":"Okba","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.addr.2021.01.001_bb0180","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/cid\/ciaa310","article-title":"Profiling early humoral response to diagnose novel coronavirus disease (COVID-19)","volume":"71","author":"Guo","year":"2020","journal-title":"Clin. Infect. Dis.: Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.addr.2021.01.001_bb0185","doi-asserted-by":"crossref","first-page":"6337","DOI":"10.4049\/jimmunol.181.9.6337","article-title":"Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV","volume":"181","author":"Yasui","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0190","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41423-020-0400-4","article-title":"Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine","volume":"17","author":"Tai","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"6483","key":"10.1016\/j.addr.2021.01.001_bb0195","first-page":"1260","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0200","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.addr.2021.01.001_bb0205","first-page":"92","article-title":"The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin","volume":"5","author":"Xia","year":"2020","journal-title":"Signal Trans. Targ. Therapy"},{"key":"10.1016\/j.addr.2021.01.001_bb0210","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12967-020-02392-y","article-title":"SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines","volume":"18","author":"Salvatori","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.addr.2021.01.001_bb0215","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/2965cfae-b77d-4014-8b7b-236e01a35492","article-title":"Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus","volume":"7","author":"Tseng","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2021.01.001_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030237","article-title":"Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants","volume":"3","author":"ter Meulen","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.addr.2021.01.001_bb0225","series-title":"WIPO","article-title":"Chimeric molecules and uses thereof","author":"Chappell","year":"2018"},{"key":"10.1016\/j.addr.2021.01.001_bb0230","series-title":"Molecular Clamp Stabilised Spike Protein For Protection Against SARS- CoV-2","author":"Watterson","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0235","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.01.001_bb0240","doi-asserted-by":"crossref","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","article-title":"Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen","volume":"114","author":"Pallesen","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2021.01.001_bb0245","article-title":"Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19","author":"Kuo","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0250","doi-asserted-by":"crossref","first-page":"8953","DOI":"10.1038\/s41598-017-09518-1","article-title":"Improvement of pharmacokinetic profile of TRAIL via trimer-tag enhances its antitumor activity in vivo","volume":"7","author":"Liu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2021.01.001_bb0255","article-title":"Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C\/B' HIV-1 candidate vaccine","volume":"5","author":"Vasan","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2021.01.001_bb0260","doi-asserted-by":"crossref","first-page":"10324","DOI":"10.1128\/JVI.00480-13","article-title":"An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody","volume":"87","author":"Petrovsky","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.01.001_bb0265","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1128\/CVI.00019-14","article-title":"Advax-adjuvanted recombinant protective antigen provides protection against inhalational anthrax that is further enhanced by addition of murabutide adjuvant","volume":"21","author":"Feinen","year":"2014","journal-title":"Clin. Vaccine Immunol.: CVI"},{"key":"10.1016\/j.addr.2021.01.001_bb0270","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1016\/j.vaccine.2014.09.034","article-title":"Immunogenicity and safety of Advax, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study","volume":"32","author":"Gordon","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0275","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1016\/j.vaccine.2015.09.030","article-title":"Advax, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety","volume":"33","author":"Petrovsky","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0280","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ebiom.2016.11.015","article-title":"Advax, a delta inulin microparticle, potentiates in-built adjuvant property of co-administered vaccines","volume":"15","author":"Hayashi","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.addr.2021.01.001_bb0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2017.1279765","article-title":"Panblok-H1+advax H1N1\/2009pdm vaccine: insights into rapid development of a delta inulin adjuvanted recombinant pandemic influenza vaccine","volume":"13","author":"Honda-Okubo","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0290","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jconrel.2018.09.006","article-title":"Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge","volume":"288","author":"Tomar","year":"2018","journal-title":"J. Control. Rel.: Off. J. Control. Rel. Soc."},{"key":"10.1016\/j.addr.2021.01.001_bb0295","article-title":"Development of unique Australian COVID-19 vaccine halted","author":"Norville","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.01.001_bb0300","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","article-title":"A Universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS","volume":"182","author":"Dai","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.addr.2021.01.001_bb0305","series-title":"COVAXX Announces First Multitope Peptide-Based Vaccine to Enter Human Trials","author":"PipelineReviews","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0310","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41577-020-0323-4","article-title":"COVID-19 vaccine design: the Janus face of immune enhancement","volume":"20","author":"Hotez","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0315","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/136419","article-title":"Comparative evaluation of recombinant protein production in different biofactories: the green perspective","volume":"2014","author":"Merlin","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.addr.2021.01.001_bb0320","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3390\/pr7080476","article-title":"Recombinant proteins for industrial versus pharmaceutical purposes: a review of process and pricing","volume":"7","author":"Puetz","year":"2019","journal-title":"Processes"},{"key":"10.1016\/j.addr.2021.01.001_bb0325","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3389\/fmicb.2014.00172","article-title":"Recombinant protein expression in Escherichia coli: advances and challenges","volume":"5","author":"Rosano","year":"2014","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.addr.2021.01.001_bb0330","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4155\/pbp.14.8","article-title":"Biopharmaceutical protein production by Saccharomyces cerevisiae: current state and future prospects","volume":"2","author":"Huang","year":"2014","journal-title":"Pharm. Bioprocess."},{"key":"10.1016\/j.addr.2021.01.001_bb0335","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/07853890.2017.1407035","article-title":"Understanding modern-day vaccines: what you need to know","volume":"50","author":"Vetter","year":"2018","journal-title":"Ann. Med."},{"key":"10.1016\/j.addr.2021.01.001_bb0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0950268806007096","article-title":"The Lyme vaccine: a cautionary tale","volume":"135","author":"Nigrovic","year":"2007","journal-title":"Epidemiol. Infect."},{"key":"10.1016\/j.addr.2021.01.001_bb0345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113294","article-title":"Design and development of a novel vaccine for protection against Lyme borreliosis","volume":"9","author":"Comstedt","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2021.01.001_bb0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184357","article-title":"The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes","volume":"12","author":"Comstedt","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2021.01.001_bb0355","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1080\/00325481.2016.1203238","article-title":"Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba(R))","volume":"128","author":"Gandhi","year":"2016","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.addr.2021.01.001_bb0360","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40259-015-0139-0","article-title":"Bivalent rLP2086 vaccine (Trumenba((R))): a review in active immunization against invasive meningococcal group b disease in individuals aged 10-25 years","volume":"29","author":"Shirley","year":"2015","journal-title":"BioDrugs: Clin. Immunother. Biopharm. Gene Therapy"},{"key":"10.1016\/j.addr.2021.01.001_bb0365","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/14760584.2017.1308828","article-title":"Emerging experience with meningococcal serogroup B protein vaccines","volume":"16","author":"Toneatto","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2021.01.001_bb0370","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/B978-0-12-420070-8.00012-X","article-title":"Protein expression-yeast","volume":"536","author":"Nielsen","year":"2014","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.addr.2021.01.001_bb0375","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/298347a0","article-title":"Synthesis and assembly of hepatitis B virus surface antigen particles in yeast","volume":"298","author":"Valenzuela","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.01.001_bb0380","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1590\/S1679-45082013000400027","article-title":"Vaccination against human papillomavirus","volume":"11","author":"Mello","year":"2013","journal-title":"Einstein"},{"key":"10.1016\/j.addr.2021.01.001_bb0385","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nprot.2008.213","article-title":"Engineering complex-type N-glycosylation in Pichia pastoris using GlycoSwitch technology","volume":"4","author":"Jacobs","year":"2009","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.addr.2021.01.001_bb0390","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","article-title":"Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike","volume":"584","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.01.001_bb0395","series-title":"Coronavirus|U.S.-Based Baylor College of Medicine Ties Up with India\u2019s Biological E for COVID-19 Vaccine","author":"PTI","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0400","series-title":"Biological E. Limited Starts Phase I\/II Clinical Trial of its COVID-19 Vaccine Candidate","author":"Dynavax","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0405","doi-asserted-by":"crossref","first-page":"648","DOI":"10.4161\/hv.27464","article-title":"Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate","volume":"10","author":"Chen","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0410","article-title":"Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with alum induces protective immunity and reduces immune enhancement","author":"Chen","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0415","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3389\/fbioe.2019.00420","article-title":"Recent developments in bioprocessing of recombinant proteins: expression hosts and process development","volume":"7","author":"Tripathi","year":"2019","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.addr.2021.01.001_bb0420","first-page":"20","article-title":"Recombinant glycoprotein E of varicella zoster virus contains glycan-peptide motifs that modulate B cell epitopes into discrete immunological signatures","author":"Norden","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2021.01.001_bb0425","first-page":"2156","article-title":"Production of human beta interferon in insect cells infected with a baculovirus expression vector","volume":"3","author":"Smith","year":"1983","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.addr.2021.01.001_bb0430","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nbt1095","article-title":"Baculovirus as versatile vectors for protein expression in insect and mammalian cells","volume":"23","author":"Kost","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2021.01.001_bb0435","first-page":"47","article-title":"Trends in the development of baculovirus expression vectors","volume":"6","author":"Luckow","year":"1988","journal-title":"Bio\/Technology"},{"key":"10.1016\/j.addr.2021.01.001_bb0440","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/bit.260361108","article-title":"High-level recombinant protein production in bioreactors using the baculovirus-insect cell expression system","volume":"36","author":"Caron","year":"1990","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.addr.2021.01.001_bb0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/btpr.1842","article-title":"Protein production using the baculovirus-insect cell expression system","volume":"30","author":"Contreras-Gomez","year":"2013","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.addr.2021.01.001_bb0450","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.2174\/138945007782151360","article-title":"Protein N-glycosylation in the baculovirus-insect cell system","volume":"8","author":"Shi","year":"2007","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.addr.2021.01.001_bb0455","series-title":"BAT Working on Potential COVID-19 Vaccine through US Bio-tech Subsidiary","author":"BAT","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0460","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1104\/pp.124.3.927","article-title":"Production of recombinant proteins in tobacco guttation fluid","volume":"124","author":"Komarnytsky","year":"2000","journal-title":"Plant Physiol."},{"key":"10.1016\/j.addr.2021.01.001_bb0465","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.4161\/21645515.2014.980199","article-title":"New tools for NTD vaccines: A case study of quality control assays for product development of the human hookworm vaccine Na-APR-1M74","volume":"11","author":"Pearson","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0470","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1080\/21645515.2015.1036207","article-title":"Expression, purification, and characterization of the Necator americanus aspartic protease-1 (Na-APR-1 (M74)) antigen, a component of the bivalent human hookworm vaccine","volume":"11","author":"Seid","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0475","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.biotechadv.2009.11.008","article-title":"Tobacco, a highly efficient green bioreactor for production of therapeutic proteins","volume":"28","author":"Tremblay","year":"2010","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.addr.2021.01.001_bb0480","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/4216060","article-title":"A brief reminder of systems of production and chromatography-based recovery of recombinant protein biopharmaceuticals","volume":"2019","author":"Owczarek","year":"2019","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.addr.2021.01.001_bb0485","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1387-2656(07)13004-0","article-title":"Preparation of recombinant vaccines","volume":"13","author":"Soler","year":"2007","journal-title":"Biotechnol. Annu. Rev."},{"key":"10.1016\/j.addr.2021.01.001_bb0490","series-title":"Development and Licensure of Vaccines to Prevent COVID-19: Guidance for Industry","author":"FDA","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0495","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13223-018-0305-2","article-title":"Unraveling the enigma: elucidating the relationship between the physicochemical properties of aluminium-based adjuvants and their immunological mechanisms of action","volume":"14","author":"Shardlow","year":"2018","journal-title":"Allergy Asthma Clin. Immunol.: Off. J. Can. Soc. Allergy Clin. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0500","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/21645515.2014.1004026","article-title":"Advances in aluminum hydroxide-based adjuvant research and its mechanism","volume":"11","author":"He","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0505","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1128\/JVI.02980-14","article-title":"Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology","volume":"89","author":"Honda-Okubo","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.01.001_bb0510","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41577-020-0358-6","article-title":"COVID-19 vaccines: neutralizing antibodies and the alum advantage","volume":"20","author":"Hotez","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0515","series-title":"Developing a Low-Cost and Accessible COVID-19 Vaccine for Global Health","author":"Hotez","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0520","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1080\/21645515.2018.1495301","article-title":"Immunology and efficacy of MF59-adjuvanted vaccines","volume":"14","author":"Ko","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0525","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1586\/14760584.6.5.699","article-title":"MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection","volume":"6","author":"O'Hagan","year":"2007","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2021.01.001_bb0530","series-title":"Adjuvanted Flu Vaccine","author":"CDC","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0535","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1002\/1521-4141(2001010)31:10<2910::AID-IMMU2910>3.0.CO;2-3","article-title":"Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis","volume":"31","author":"Dupuis","year":"2001","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0540","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.4049\/jimmunol.153.9.4029","article-title":"Systemic cytokine profiles in BALB\/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants","volume":"153","author":"Valensi","year":"1994","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0545","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/erv.11.23","article-title":"MF59 adjuvant: the best insurance against influenza strain diversity","volume":"10","author":"O'Hagan","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2021.01.001_bb0550","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00011-020-01377-3","article-title":"SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus","volume":"69","author":"Oberemok","year":"2020","journal-title":"Inflamm. Res.: Off. J. Eur. Histam. Res. Soc. \u2026 [et al.]"},{"key":"10.1016\/j.addr.2021.01.001_bb0555","series-title":"Vaccine Adjuvants: Methods and Protocols","first-page":"15","article-title":"Development of the CpG adjuvant 1018: A case study","author":"Campbell","year":"2016"},{"key":"10.1016\/j.addr.2021.01.001_bb0560","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1016\/j.vaccine.2019.04.048","article-title":"Safety of AS03-adjuvanted influenza vaccines: a review of the evidence","volume":"37","author":"Cohet","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0565","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1080\/21645515.2016.1168954","article-title":"Evaluation of potential immunogenicity differences between Pandemrix\u2122 and Arepanrix\u2122","volume":"12","author":"Canelle","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0570","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3389\/fimmu.2017.01760","article-title":"AS03- and MF59-adjuvanted influenza vaccines in children","volume":"8","author":"Wilkins","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0575","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12026-018-8991-x","article-title":"Matrix-M adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice","volume":"66","author":"Magnusson","year":"2018","journal-title":"Immunol. Res."},{"key":"10.1016\/j.addr.2021.01.001_bb0580","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.vaccine.2013.01.039","article-title":"Immune enhancing properties of the novel matrix-M adjuvant leads to potentiated immune responses to an influenza vaccine in mice","volume":"31","author":"Magnusson","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0585","first-page":"49","article-title":"Induction of virus-specific immunity by iscoms","volume":"92","author":"Osterhaus","year":"1998","journal-title":"Dev. Biol. Stand."},{"key":"10.1016\/j.addr.2021.01.001_bb0590","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1016\/j.vaccine.2011.08.042","article-title":"Evaluation of a virosomal H5N1 vaccine formulated with matrix M adjuvant in a phase I clinical trial","volume":"29","author":"Cox","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0595","series-title":"Study of Parenterally Administrated Adjuvanted Seasonal Influenza Vaccine in Healthy Elderly Volunteers","author":"Clinicaltrials_gov","year":"2011"},{"key":"10.1016\/j.addr.2021.01.001_bb0600","series-title":"A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1\u2122 Adjuvant","author":"Clinicaltrials_gov","year":"2014"},{"key":"10.1016\/j.addr.2021.01.001_bb0605","series-title":"Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1\u2122 Adjuvants In Clinically-Stable Older Adults","author":"Clinicaltrials_gov","year":"2017"},{"key":"10.1016\/j.addr.2021.01.001_bb0610","series-title":"A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, Administered With and Without Matrix-M1","author":"Clinicaltrials_gov","year":"2019"},{"key":"10.1016\/j.addr.2021.01.001_bb0615","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jaci.2019.03.035","article-title":"Randomized controlled trial demonstrating the benefits of delta inulin adjuvanted immunotherapy in patients with bee venom allergy","volume":"144","author":"Heddle","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0620","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","article-title":"Immunological considerations for COVID-19 vaccine strategies","volume":"20","author":"Jeyanathan","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0625","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.micinf.2020.04.005","article-title":"The potential role of Th17 immune responses in coronavirus immunopathology and vaccine-induced immune enhancement","volume":"22","author":"Hotez","year":"2020","journal-title":"Microbes Infect."},{"key":"10.1016\/j.addr.2021.01.001_bb0630","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.4049\/jimmunol.0800531","article-title":"Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth Onchocerca volvulus, can directly bind and activate antigen-presenting cells","volume":"182","author":"He","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0635","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.0141-9838.2004.00685.x","article-title":"Ov-ASP-1, the Onchocerca volvulus homologue of the activation associated secreted protein family is immunostimulatory and can induce protective anti-larval immunity","volume":"26","author":"MacDonald","year":"2004","journal-title":"Parasite Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0640","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1016\/j.vaccine.2008.07.028","article-title":"Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccines","volume":"26","author":"Xiao","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0645","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1743-422X-7-9","article-title":"An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses","volume":"7","author":"Zhao","year":"2010","journal-title":"Virol. J."},{"key":"10.1016\/j.addr.2021.01.001_bb0650","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00215-18","article-title":"The mucosal vaccine adjuvant LT(R192G\/L211A) or dmLT","volume":"3","author":"Clements","year":"2018","journal-title":"mSphere"},{"key":"10.1016\/j.addr.2021.01.001_bb0655","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.vaccine.2015.02.069","article-title":"The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model","volume":"33","author":"Norton","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0660","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bbi.2020.05.057","article-title":"The role of IgA in COVID-19","volume":"87","author":"Chao","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.addr.2021.01.001_bb0665","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1586\/14760584.2015.1081067","article-title":"Effect of vaccine administration modality on immunogenicity and efficacy","volume":"14","author":"Zhang","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2021.01.001_bb0670","first-page":"2145","article-title":"Intradermal injection, as opposed to subcutaneous injection, enhances immunogenicity and suppresses tumorigenicity of tumor cells","volume":"63","author":"Bonnotte","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2021.01.001_bb0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102743","article-title":"Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development","volume":"55","author":"Kim","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.addr.2021.01.001_bb0680","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.ijbiomac.2020.05.239","article-title":"A recombinant Lactobacillus plantarum strain expressing the spike protein of SARS-CoV-2","volume":"160","author":"Wang","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.addr.2021.01.001_bb0685","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S1473-3099(15)00266-2","article-title":"High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial","volume":"15","author":"Liebowitz","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.addr.2021.01.001_bb0690","series-title":"Vaxart's oral COVID-19 Tablet Vaccine to Enter Clinical Trials","author":"Arthur","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0695","series-title":"Merck Looks to Lower Barriers to COVID-19 Vaccination with Oral Approach","author":"Eaton","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0700","series-title":"Chinese Covid-19 Vaccine Candidate Becomes First Nasal Spray to Start Clinical Trial","author":"Simin","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0705","series-title":"Nasal Spray Vaccine for Covid-19","author":"ClinicalTrialsArena","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0710","series-title":"Single-Dose Intranasal COVID-19 Vaccine","author":"Altimmune","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0715","series-title":"FluGen, Bharat Biotech to develop CoroFlu, a coronavirus vaccine","author":"University_of_Wisconsin, UW\u2013Madison","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0720","series-title":"Fundamentals and Applications of Controlled Release Drug Delivery","author":"Siepmann","year":"2012"},{"key":"10.1016\/j.addr.2021.01.001_bb0725","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8303648","article-title":"Alternative methods of vaccine delivery: an overview of edible and intradermal vaccines","volume":"2019","author":"Criscuolo","year":"2019","journal-title":"J Immunol Res"},{"key":"10.1016\/j.addr.2021.01.001_bb0730","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1016\/j.vaccine.2012.05.011","article-title":"Survey of the prevalence of immunization non-compliance due to needle fears in children and adults","volume":"30","author":"Taddio","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0735","doi-asserted-by":"crossref","first-page":"7214","DOI":"10.1016\/j.vaccine.2006.06.043","article-title":"Physiochemical and functional characterization of antigen proteins eluted from aluminum hydroxide adjuvant","volume":"24","author":"Hutcheon","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0740","doi-asserted-by":"crossref","first-page":"13406","DOI":"10.1074\/jbc.M500687200","article-title":"Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens","volume":"280","author":"Jones","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2021.01.001_bb0745","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijpharm.2005.04.037","article-title":"Preparation of coated nanoparticles for a new mucosal vaccine delivery system","volume":"299","author":"Borges","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2021.01.001_bb0750","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41541-020-0190-9","article-title":"New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes","volume":"5","author":"Amacker","year":"2020","journal-title":"NPJ Vaccines"},{"issue":"Suppl. 1","key":"10.1016\/j.addr.2021.01.001_bb0755","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.vaccine.2005.04.026","article-title":"The virosome concept for influenza vaccines","volume":"23","author":"Huckriede","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0760","series-title":"Mymetics Starts Second Preclinical Study for Virosome-based Covid-19 Vaccine","author":"Kempers","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0765","series-title":"A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0770","series-title":"Novavax Initiates Efficacy Trial of COVID-19 Vaccine in South Africa","author":"Novavax","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0775","series-title":"COVID-19 Tracker: Warp Speed Chief Eyes Timeline for Pfizer, Moderna, AZ Shot Data; FDA can Reveal Safety info If Vaccine Makers Don't, Official Says, Fierce_Pharma","author":"Sagonowsky","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0780","series-title":"Dynavax Announces First Participants Dosed in Phase 1 Clinical Trial Evaluating Clover Biopharmaceuticals\u2019 COVID-19 S-Trimer Vaccine Candidate with CpG 1018 Adjuvant","author":"Biospace","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0785","series-title":"Clover Announces Formation of a Global Scientific Advisory Board for its COVID-19 Vaccine Program","author":"Clover_Biopharma","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0790","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.01.001_bb0795","article-title":"Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment","author":"Malladi","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2021.01.001_bb0800","article-title":"A vaccine displaying a trimeric influenza-a ha stem protein on capsid-like particles elicits potent and long-lasting protection in mice","volume":"8","author":"Thrane","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.addr.2021.01.001_bb0805","series-title":"COVID-19 cVLP Vaccine Demonstrated as Effective in Mice","author":"de Jongh","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0810","series-title":"ExpreS2ion Announces Successful Manufacturing of the cVLP COVID-19 Vaccine and Further Positive Updates","author":"Frandsen","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0815","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s12026-013-8468-x","article-title":"Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer and infectious diseases","volume":"57","author":"Strbo","year":"2013","journal-title":"Immunol. Res."},{"key":"10.1016\/j.addr.2021.01.001_bb0820","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jcpa.2014.01.004","article-title":"The pathology and pathogenesis of experimental severe acute respiratory syndrome and influenza in animal models","volume":"151","author":"van den Brand","year":"2014","journal-title":"J. Comp. Pathol."},{"key":"10.1016\/j.addr.2021.01.001_bb0825","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1128\/CVI.00455-14","article-title":"Multiple low-dose challenges in a rhesus macaque AIDS vaccine trial result in an evolving host response that affects protective outcome","volume":"21","author":"Selinger","year":"2014","journal-title":"Clin. Vaccine Immunol.: CVI"},{"key":"10.1016\/j.addr.2021.01.001_bb0830","article-title":"Induction of SARS-CoV-2 protein S-specific CD8+T cells in the lungs of gp96-Ig-S vaccinated mice","author":"Fisher","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0835","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01083-20","article-title":"COVID-19 vaccines: \u201cWarp Speed\u201d needs mind melds, not warped minds","volume":"94","author":"Moore","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.01.001_bb0840","series-title":"Correlates and Disparities of COVID-19 Vaccine Hesitancy","author":"Callaghan","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0845","article-title":"Protein-based Covid-19 vaccines could overshadow rivals","author":"King","year":"2020","journal-title":"Chem. World"},{"key":"10.1016\/j.addr.2021.01.001_bb0850","series-title":"Pfizer, Moderna's Coronavirus Shot Rollouts Could Freeze Up, Experts Say, Citing Cold-storage Needs","author":"Blankenship","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0855","article-title":"Safety and immunogenicity of heterologous and homologous two dose regimens of Ad26- and MVA-vectored ebola vaccines: a randomized, controlled phase 1 study","author":"Goldstein","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2021.01.001_bb0860","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines2030624","article-title":"Developments in viral vector-based vaccines","volume":"2","author":"Ura","year":"2014","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.addr.2021.01.001_bb0865","doi-asserted-by":"crossref","first-page":"11434","DOI":"10.1128\/JVI.78.20.11434-11438.2004","article-title":"Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors","volume":"78","author":"Casimiro","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.01.001_bb0870","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2021.01.001_bb0875","article-title":"Safety and immunogenicity of the Ad26.RSV.preF investigational vaccine coadministered with an influenza vaccine in older adults","author":"Sadoff","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2021.01.001_bb0880","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An Mrna vaccine against SARS-CoV-2 - preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.01.001_bb0885","article-title":"RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study","author":"Walsh","year":"2020","journal-title":"medRxiv: Preprint Server Health Sci."},{"key":"10.1016\/j.addr.2021.01.001_bb0890","series-title":"After Admitting Mistake, AstraZeneca Faces Difficult Questions About Its Vaccine","author":"Robbins","year":"2020"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X21000016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X21000016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T12:42:48Z","timestamp":1673440968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X21000016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":178,"alternative-id":["S0169409X21000016"],"URL":"http:\/\/dx.doi.org\/10.1016\/j.addr.2021.01.001","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":["Pharmaceutical Science"],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant protein vaccines, a proven approach against coronavirus pandemics","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2021.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}
{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T19:13:37Z","timestamp":1679080417095},"reference-count":178,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.addr.2021.01.001","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T02:52:17Z","timestamp":1610074337000},"page":"71-82","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"title":["Recombinant protein vaccines, a proven approach against coronavirus pandemics"],"prefix":"10.1016","volume":"170","author":[{"given":"Jeroen","family":"Pollet","sequence":"first","affiliation":[]},{"given":"Wen-Hsiang","family":"Chen","sequence":"additional","affiliation":[]},{"given":"Ulrich","family":"Strych","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2021.01.001_bb0005","series-title":"Coronavirus: Sputnik V vaccine rushed out to wary Russians","author":"Rainsford","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0010","article-title":"China drugmaker fact-checks claim that its leading COVID vaccine is 97% effective","author":"McGregor","year":"2020","journal-title":"Fortune"},{"key":"10.1016\/j.addr.2021.01.001_bb0015","series-title":"As U.K. Begins Vaccinations, A Glimpse of Life After Covid","author":"Mueller","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0020","series-title":"Canada Authorizes Use Of Pfizer COVID-19 Vaccine","author":"Dwyer","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0025","series-title":"DRAFT Landscape of COVID-19 Candidate Vaccines","author":"WHO","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0030","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.01.001_bb0035","series-title":"A Study Looking at the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults at Risk for SARS-CoV-2","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0040","series-title":"Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With\/Without Matrix-M Adjuvant","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0045","article-title":"Sanofi-GSK covid-19 vaccine is set back by lab mistake","author":"Dalton","year":"2020","journal-title":"Wall Street J."},{"key":"10.1016\/j.addr.2021.01.001_bb0050","series-title":"SCB-2019 as COVID-19 Vaccine","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0055","article-title":"S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates","author":"Liang","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0060","series-title":"A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0065","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-77077-z","article-title":"Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19","volume":"10","author":"Kuo","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2021.01.001_bb0070","series-title":"Monovalent Recombinant COVID19 Vaccine (COVAX19)","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0075","series-title":"Vaxine and Medytox \u2013 COVAX-19\u00ae","author":"Genengnews","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0080","series-title":"A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0085","series-title":"Biological E\u2019s Novel Covid-19 Vaccine of SARS-CoV-2 for Protection Against Covid-19 Disease","author":"CTRI","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0090","article-title":"SARS-CoV-2 RBD219-N1C1: a yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice","author":"Pollet","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0095","article-title":"Cloning, expression and biophysical characterization of a yeast-expressed recombinant SARS-CoV-2 receptor binding domain COVID-19 vaccine candidate","author":"Chen","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0100","author":"RPCEC","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0105","series-title":"Soberana is Cuba\u2019s, The First Candidate Vaccine Against COVID-19 in Latin America and the Caribbean, Granma - The OFFICIAL VOICE OF THE COMMUNIST PARTY OF CUBA CENTRAL COMMITTEE","author":"Morales","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0110","series-title":"KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0115","series-title":"Clinical Study of Recombinant Novel Coronavirus Vaccine","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0120","series-title":"A Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial of the Effectiveness and Safety of Inoculation of Recombinant New Coronavirus Vaccine (CHO cells) in the Prevention of COVID-19 in People 18 Years and Older","author":"CHICTR","year":"2020"},{"issue":"7830","key":"10.1016\/j.addr.2021.01.001_bb0125","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-020-2599-8","article-title":"A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity","volume":"586","author":"Yang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.01.001_bb0130","series-title":"Recombinant COVID-19 Vaccine (Sf9 cells) Phase II Clinical Trial","author":"CHICTR","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0135","series-title":"Randomized Double Blind, Placebo Controlled Phase I Trial for Anti Novel Coronavirus Pneumonia (COVID-19) Recombinant Vaccine (Sf9)","author":"CHICTR","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0140","series-title":"COVAXX \u2013 UB-612","author":"Genetic_Engineering&Biotechnology_News","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0145","series-title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0150","series-title":"Study of the Safety, Reactogenicity and Immunogenicity of \u201cEpiVacCorona\u201d Vaccine for the Prevention of COVID-19 (EpiVacCorona)","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0155","series-title":"Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults (pVAC)","author":"Clinicaltrials_gov","year":"2020"},{"issue":"1","key":"10.1016\/j.addr.2021.01.001_bb0160","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41590-020-00808-x","article-title":"SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition","volume":"22","author":"Nelde","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0165","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","article-title":"Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.addr.2021.01.001_bb0170","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00512-20","article-title":"Laboratory diagnosis of COVID-19: current issues and challenges","volume":"58","author":"Tang","year":"2020","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.addr.2021.01.001_bb0175","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3201\/eid2607.200841","article-title":"Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients","volume":"26","author":"Okba","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.addr.2021.01.001_bb0180","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/cid\/ciaa310","article-title":"Profiling early humoral response to diagnose novel coronavirus disease (COVID-19)","volume":"71","author":"Guo","year":"2020","journal-title":"Clin. Infect. Dis.: Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.addr.2021.01.001_bb0185","doi-asserted-by":"crossref","first-page":"6337","DOI":"10.4049\/jimmunol.181.9.6337","article-title":"Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV","volume":"181","author":"Yasui","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0190","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41423-020-0400-4","article-title":"Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine","volume":"17","author":"Tai","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"6483","key":"10.1016\/j.addr.2021.01.001_bb0195","first-page":"1260","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0200","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.addr.2021.01.001_bb0205","first-page":"92","article-title":"The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin","volume":"5","author":"Xia","year":"2020","journal-title":"Signal Trans. Targ. Therapy"},{"key":"10.1016\/j.addr.2021.01.001_bb0210","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12967-020-02392-y","article-title":"SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines","volume":"18","author":"Salvatori","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.addr.2021.01.001_bb0215","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/2965cfae-b77d-4014-8b7b-236e01a35492","article-title":"Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus","volume":"7","author":"Tseng","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2021.01.001_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030237","article-title":"Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants","volume":"3","author":"ter Meulen","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.addr.2021.01.001_bb0225","series-title":"WIPO","article-title":"Chimeric molecules and uses thereof","author":"Chappell","year":"2018"},{"key":"10.1016\/j.addr.2021.01.001_bb0230","series-title":"Molecular Clamp Stabilised Spike Protein For Protection Against SARS- CoV-2","author":"Watterson","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0235","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.01.001_bb0240","doi-asserted-by":"crossref","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","article-title":"Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen","volume":"114","author":"Pallesen","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2021.01.001_bb0245","article-title":"Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19","author":"Kuo","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0250","doi-asserted-by":"crossref","first-page":"8953","DOI":"10.1038\/s41598-017-09518-1","article-title":"Improvement of pharmacokinetic profile of TRAIL via trimer-tag enhances its antitumor activity in vivo","volume":"7","author":"Liu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2021.01.001_bb0255","article-title":"Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C\/B' HIV-1 candidate vaccine","volume":"5","author":"Vasan","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2021.01.001_bb0260","doi-asserted-by":"crossref","first-page":"10324","DOI":"10.1128\/JVI.00480-13","article-title":"An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody","volume":"87","author":"Petrovsky","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.01.001_bb0265","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1128\/CVI.00019-14","article-title":"Advax-adjuvanted recombinant protective antigen provides protection against inhalational anthrax that is further enhanced by addition of murabutide adjuvant","volume":"21","author":"Feinen","year":"2014","journal-title":"Clin. Vaccine Immunol.: CVI"},{"key":"10.1016\/j.addr.2021.01.001_bb0270","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1016\/j.vaccine.2014.09.034","article-title":"Immunogenicity and safety of Advax, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study","volume":"32","author":"Gordon","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0275","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1016\/j.vaccine.2015.09.030","article-title":"Advax, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety","volume":"33","author":"Petrovsky","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0280","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ebiom.2016.11.015","article-title":"Advax, a delta inulin microparticle, potentiates in-built adjuvant property of co-administered vaccines","volume":"15","author":"Hayashi","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.addr.2021.01.001_bb0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2017.1279765","article-title":"Panblok-H1+advax H1N1\/2009pdm vaccine: insights into rapid development of a delta inulin adjuvanted recombinant pandemic influenza vaccine","volume":"13","author":"Honda-Okubo","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0290","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jconrel.2018.09.006","article-title":"Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge","volume":"288","author":"Tomar","year":"2018","journal-title":"J. Control. Rel.: Off. J. Control. Rel. Soc."},{"key":"10.1016\/j.addr.2021.01.001_bb0295","article-title":"Development of unique Australian COVID-19 vaccine halted","author":"Norville","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.01.001_bb0300","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","article-title":"A Universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS","volume":"182","author":"Dai","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.addr.2021.01.001_bb0305","series-title":"COVAXX Announces First Multitope Peptide-Based Vaccine to Enter Human Trials","author":"PipelineReviews","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0310","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41577-020-0323-4","article-title":"COVID-19 vaccine design: the Janus face of immune enhancement","volume":"20","author":"Hotez","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0315","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/136419","article-title":"Comparative evaluation of recombinant protein production in different biofactories: the green perspective","volume":"2014","author":"Merlin","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.addr.2021.01.001_bb0320","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3390\/pr7080476","article-title":"Recombinant proteins for industrial versus pharmaceutical purposes: a review of process and pricing","volume":"7","author":"Puetz","year":"2019","journal-title":"Processes"},{"key":"10.1016\/j.addr.2021.01.001_bb0325","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3389\/fmicb.2014.00172","article-title":"Recombinant protein expression in Escherichia coli: advances and challenges","volume":"5","author":"Rosano","year":"2014","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.addr.2021.01.001_bb0330","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4155\/pbp.14.8","article-title":"Biopharmaceutical protein production by Saccharomyces cerevisiae: current state and future prospects","volume":"2","author":"Huang","year":"2014","journal-title":"Pharm. Bioprocess."},{"key":"10.1016\/j.addr.2021.01.001_bb0335","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/07853890.2017.1407035","article-title":"Understanding modern-day vaccines: what you need to know","volume":"50","author":"Vetter","year":"2018","journal-title":"Ann. Med."},{"key":"10.1016\/j.addr.2021.01.001_bb0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0950268806007096","article-title":"The Lyme vaccine: a cautionary tale","volume":"135","author":"Nigrovic","year":"2007","journal-title":"Epidemiol. Infect."},{"key":"10.1016\/j.addr.2021.01.001_bb0345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113294","article-title":"Design and development of a novel vaccine for protection against Lyme borreliosis","volume":"9","author":"Comstedt","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2021.01.001_bb0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184357","article-title":"The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes","volume":"12","author":"Comstedt","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2021.01.001_bb0355","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1080\/00325481.2016.1203238","article-title":"Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba(R))","volume":"128","author":"Gandhi","year":"2016","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.addr.2021.01.001_bb0360","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40259-015-0139-0","article-title":"Bivalent rLP2086 vaccine (Trumenba((R))): a review in active immunization against invasive meningococcal group b disease in individuals aged 10-25 years","volume":"29","author":"Shirley","year":"2015","journal-title":"BioDrugs: Clin. Immunother. Biopharm. Gene Therapy"},{"key":"10.1016\/j.addr.2021.01.001_bb0365","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/14760584.2017.1308828","article-title":"Emerging experience with meningococcal serogroup B protein vaccines","volume":"16","author":"Toneatto","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2021.01.001_bb0370","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/B978-0-12-420070-8.00012-X","article-title":"Protein expression-yeast","volume":"536","author":"Nielsen","year":"2014","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.addr.2021.01.001_bb0375","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/298347a0","article-title":"Synthesis and assembly of hepatitis B virus surface antigen particles in yeast","volume":"298","author":"Valenzuela","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.01.001_bb0380","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1590\/S1679-45082013000400027","article-title":"Vaccination against human papillomavirus","volume":"11","author":"Mello","year":"2013","journal-title":"Einstein"},{"key":"10.1016\/j.addr.2021.01.001_bb0385","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nprot.2008.213","article-title":"Engineering complex-type N-glycosylation in Pichia pastoris using GlycoSwitch technology","volume":"4","author":"Jacobs","year":"2009","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.addr.2021.01.001_bb0390","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","article-title":"Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike","volume":"584","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.01.001_bb0395","series-title":"Coronavirus|U.S.-Based Baylor College of Medicine Ties Up with India\u2019s Biological E for COVID-19 Vaccine","author":"PTI","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0400","series-title":"Biological E. Limited Starts Phase I\/II Clinical Trial of its COVID-19 Vaccine Candidate","author":"Dynavax","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0405","doi-asserted-by":"crossref","first-page":"648","DOI":"10.4161\/hv.27464","article-title":"Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate","volume":"10","author":"Chen","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0410","article-title":"Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with alum induces protective immunity and reduces immune enhancement","author":"Chen","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0415","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3389\/fbioe.2019.00420","article-title":"Recent developments in bioprocessing of recombinant proteins: expression hosts and process development","volume":"7","author":"Tripathi","year":"2019","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.addr.2021.01.001_bb0420","first-page":"20","article-title":"Recombinant glycoprotein E of varicella zoster virus contains glycan-peptide motifs that modulate B cell epitopes into discrete immunological signatures","author":"Norden","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2021.01.001_bb0425","first-page":"2156","article-title":"Production of human beta interferon in insect cells infected with a baculovirus expression vector","volume":"3","author":"Smith","year":"1983","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.addr.2021.01.001_bb0430","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nbt1095","article-title":"Baculovirus as versatile vectors for protein expression in insect and mammalian cells","volume":"23","author":"Kost","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2021.01.001_bb0435","first-page":"47","article-title":"Trends in the development of baculovirus expression vectors","volume":"6","author":"Luckow","year":"1988","journal-title":"Bio\/Technology"},{"key":"10.1016\/j.addr.2021.01.001_bb0440","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/bit.260361108","article-title":"High-level recombinant protein production in bioreactors using the baculovirus-insect cell expression system","volume":"36","author":"Caron","year":"1990","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.addr.2021.01.001_bb0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/btpr.1842","article-title":"Protein production using the baculovirus-insect cell expression system","volume":"30","author":"Contreras-Gomez","year":"2013","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.addr.2021.01.001_bb0450","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.2174\/138945007782151360","article-title":"Protein N-glycosylation in the baculovirus-insect cell system","volume":"8","author":"Shi","year":"2007","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.addr.2021.01.001_bb0455","series-title":"BAT Working on Potential COVID-19 Vaccine through US Bio-tech Subsidiary","author":"BAT","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0460","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1104\/pp.124.3.927","article-title":"Production of recombinant proteins in tobacco guttation fluid","volume":"124","author":"Komarnytsky","year":"2000","journal-title":"Plant Physiol."},{"key":"10.1016\/j.addr.2021.01.001_bb0465","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.4161\/21645515.2014.980199","article-title":"New tools for NTD vaccines: A case study of quality control assays for product development of the human hookworm vaccine Na-APR-1M74","volume":"11","author":"Pearson","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0470","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1080\/21645515.2015.1036207","article-title":"Expression, purification, and characterization of the Necator americanus aspartic protease-1 (Na-APR-1 (M74)) antigen, a component of the bivalent human hookworm vaccine","volume":"11","author":"Seid","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0475","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.biotechadv.2009.11.008","article-title":"Tobacco, a highly efficient green bioreactor for production of therapeutic proteins","volume":"28","author":"Tremblay","year":"2010","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.addr.2021.01.001_bb0480","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/4216060","article-title":"A brief reminder of systems of production and chromatography-based recovery of recombinant protein biopharmaceuticals","volume":"2019","author":"Owczarek","year":"2019","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.addr.2021.01.001_bb0485","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1387-2656(07)13004-0","article-title":"Preparation of recombinant vaccines","volume":"13","author":"Soler","year":"2007","journal-title":"Biotechnol. Annu. Rev."},{"key":"10.1016\/j.addr.2021.01.001_bb0490","series-title":"Development and Licensure of Vaccines to Prevent COVID-19: Guidance for Industry","author":"FDA","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0495","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13223-018-0305-2","article-title":"Unraveling the enigma: elucidating the relationship between the physicochemical properties of aluminium-based adjuvants and their immunological mechanisms of action","volume":"14","author":"Shardlow","year":"2018","journal-title":"Allergy Asthma Clin. Immunol.: Off. J. Can. Soc. Allergy Clin. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0500","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/21645515.2014.1004026","article-title":"Advances in aluminum hydroxide-based adjuvant research and its mechanism","volume":"11","author":"He","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0505","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1128\/JVI.02980-14","article-title":"Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology","volume":"89","author":"Honda-Okubo","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.01.001_bb0510","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41577-020-0358-6","article-title":"COVID-19 vaccines: neutralizing antibodies and the alum advantage","volume":"20","author":"Hotez","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0515","series-title":"Developing a Low-Cost and Accessible COVID-19 Vaccine for Global Health","author":"Hotez","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0520","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1080\/21645515.2018.1495301","article-title":"Immunology and efficacy of MF59-adjuvanted vaccines","volume":"14","author":"Ko","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0525","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1586\/14760584.6.5.699","article-title":"MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection","volume":"6","author":"O'Hagan","year":"2007","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2021.01.001_bb0530","series-title":"Adjuvanted Flu Vaccine","author":"CDC","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0535","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1002\/1521-4141(2001010)31:103.0.CO;2-3","article-title":"Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis","volume":"31","author":"Dupuis","year":"2001","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0540","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.4049\/jimmunol.153.9.4029","article-title":"Systemic cytokine profiles in BALB\/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants","volume":"153","author":"Valensi","year":"1994","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0545","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/erv.11.23","article-title":"MF59 adjuvant: the best insurance against influenza strain diversity","volume":"10","author":"O'Hagan","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2021.01.001_bb0550","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00011-020-01377-3","article-title":"SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus","volume":"69","author":"Oberemok","year":"2020","journal-title":"Inflamm. Res.: Off. J. Eur. Histam. Res. Soc. \u2026 [et al.]"},{"key":"10.1016\/j.addr.2021.01.001_bb0555","series-title":"Vaccine Adjuvants: Methods and Protocols","first-page":"15","article-title":"Development of the CpG adjuvant 1018: A case study","author":"Campbell","year":"2016"},{"key":"10.1016\/j.addr.2021.01.001_bb0560","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1016\/j.vaccine.2019.04.048","article-title":"Safety of AS03-adjuvanted influenza vaccines: a review of the evidence","volume":"37","author":"Cohet","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0565","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1080\/21645515.2016.1168954","article-title":"Evaluation of potential immunogenicity differences between Pandemrix\u2122 and Arepanrix\u2122","volume":"12","author":"Canelle","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.addr.2021.01.001_bb0570","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3389\/fimmu.2017.01760","article-title":"AS03- and MF59-adjuvanted influenza vaccines in children","volume":"8","author":"Wilkins","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0575","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12026-018-8991-x","article-title":"Matrix-M adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice","volume":"66","author":"Magnusson","year":"2018","journal-title":"Immunol. Res."},{"key":"10.1016\/j.addr.2021.01.001_bb0580","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.vaccine.2013.01.039","article-title":"Immune enhancing properties of the novel matrix-M adjuvant leads to potentiated immune responses to an influenza vaccine in mice","volume":"31","author":"Magnusson","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0585","first-page":"49","article-title":"Induction of virus-specific immunity by iscoms","volume":"92","author":"Osterhaus","year":"1998","journal-title":"Dev. Biol. Stand."},{"key":"10.1016\/j.addr.2021.01.001_bb0590","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1016\/j.vaccine.2011.08.042","article-title":"Evaluation of a virosomal H5N1 vaccine formulated with matrix M adjuvant in a phase I clinical trial","volume":"29","author":"Cox","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0595","series-title":"Study of Parenterally Administrated Adjuvanted Seasonal Influenza Vaccine in Healthy Elderly Volunteers","author":"Clinicaltrials_gov","year":"2011"},{"key":"10.1016\/j.addr.2021.01.001_bb0600","series-title":"A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1\u2122 Adjuvant","author":"Clinicaltrials_gov","year":"2014"},{"key":"10.1016\/j.addr.2021.01.001_bb0605","series-title":"Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1\u2122 Adjuvants In Clinically-Stable Older Adults","author":"Clinicaltrials_gov","year":"2017"},{"key":"10.1016\/j.addr.2021.01.001_bb0610","series-title":"A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, Administered With and Without Matrix-M1","author":"Clinicaltrials_gov","year":"2019"},{"key":"10.1016\/j.addr.2021.01.001_bb0615","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jaci.2019.03.035","article-title":"Randomized controlled trial demonstrating the benefits of delta inulin adjuvanted immunotherapy in patients with bee venom allergy","volume":"144","author":"Heddle","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0620","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","article-title":"Immunological considerations for COVID-19 vaccine strategies","volume":"20","author":"Jeyanathan","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0625","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.micinf.2020.04.005","article-title":"The potential role of Th17 immune responses in coronavirus immunopathology and vaccine-induced immune enhancement","volume":"22","author":"Hotez","year":"2020","journal-title":"Microbes Infect."},{"key":"10.1016\/j.addr.2021.01.001_bb0630","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.4049\/jimmunol.0800531","article-title":"Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth Onchocerca volvulus, can directly bind and activate antigen-presenting cells","volume":"182","author":"He","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0635","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.0141-9838.2004.00685.x","article-title":"Ov-ASP-1, the Onchocerca volvulus homologue of the activation associated secreted protein family is immunostimulatory and can induce protective anti-larval immunity","volume":"26","author":"MacDonald","year":"2004","journal-title":"Parasite Immunol."},{"key":"10.1016\/j.addr.2021.01.001_bb0640","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1016\/j.vaccine.2008.07.028","article-title":"Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccines","volume":"26","author":"Xiao","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0645","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1743-422X-7-9","article-title":"An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses","volume":"7","author":"Zhao","year":"2010","journal-title":"Virol. J."},{"key":"10.1016\/j.addr.2021.01.001_bb0650","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00215-18","article-title":"The mucosal vaccine adjuvant LT(R192G\/L211A) or dmLT","volume":"3","author":"Clements","year":"2018","journal-title":"mSphere"},{"key":"10.1016\/j.addr.2021.01.001_bb0655","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.vaccine.2015.02.069","article-title":"The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model","volume":"33","author":"Norton","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0660","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bbi.2020.05.057","article-title":"The role of IgA in COVID-19","volume":"87","author":"Chao","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.addr.2021.01.001_bb0665","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1586\/14760584.2015.1081067","article-title":"Effect of vaccine administration modality on immunogenicity and efficacy","volume":"14","author":"Zhang","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.addr.2021.01.001_bb0670","first-page":"2145","article-title":"Intradermal injection, as opposed to subcutaneous injection, enhances immunogenicity and suppresses tumorigenicity of tumor cells","volume":"63","author":"Bonnotte","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2021.01.001_bb0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102743","article-title":"Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development","volume":"55","author":"Kim","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.addr.2021.01.001_bb0680","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.ijbiomac.2020.05.239","article-title":"A recombinant Lactobacillus plantarum strain expressing the spike protein of SARS-CoV-2","volume":"160","author":"Wang","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.addr.2021.01.001_bb0685","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S1473-3099(15)00266-2","article-title":"High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial","volume":"15","author":"Liebowitz","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.addr.2021.01.001_bb0690","series-title":"Vaxart's oral COVID-19 Tablet Vaccine to Enter Clinical Trials","author":"Arthur","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0695","series-title":"Merck Looks to Lower Barriers to COVID-19 Vaccination with Oral Approach","author":"Eaton","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0700","series-title":"Chinese Covid-19 Vaccine Candidate Becomes First Nasal Spray to Start Clinical Trial","author":"Simin","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0705","series-title":"Nasal Spray Vaccine for Covid-19","author":"ClinicalTrialsArena","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0710","series-title":"Single-Dose Intranasal COVID-19 Vaccine","author":"Altimmune","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0715","series-title":"FluGen, Bharat Biotech to develop CoroFlu, a coronavirus vaccine","author":"University_of_Wisconsin, UW\u2013Madison","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0720","series-title":"Fundamentals and Applications of Controlled Release Drug Delivery","author":"Siepmann","year":"2012"},{"key":"10.1016\/j.addr.2021.01.001_bb0725","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8303648","article-title":"Alternative methods of vaccine delivery: an overview of edible and intradermal vaccines","volume":"2019","author":"Criscuolo","year":"2019","journal-title":"J Immunol Res"},{"key":"10.1016\/j.addr.2021.01.001_bb0730","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1016\/j.vaccine.2012.05.011","article-title":"Survey of the prevalence of immunization non-compliance due to needle fears in children and adults","volume":"30","author":"Taddio","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0735","doi-asserted-by":"crossref","first-page":"7214","DOI":"10.1016\/j.vaccine.2006.06.043","article-title":"Physiochemical and functional characterization of antigen proteins eluted from aluminum hydroxide adjuvant","volume":"24","author":"Hutcheon","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0740","doi-asserted-by":"crossref","first-page":"13406","DOI":"10.1074\/jbc.M500687200","article-title":"Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens","volume":"280","author":"Jones","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2021.01.001_bb0745","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijpharm.2005.04.037","article-title":"Preparation of coated nanoparticles for a new mucosal vaccine delivery system","volume":"299","author":"Borges","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2021.01.001_bb0750","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41541-020-0190-9","article-title":"New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes","volume":"5","author":"Amacker","year":"2020","journal-title":"NPJ Vaccines"},{"issue":"Suppl. 1","key":"10.1016\/j.addr.2021.01.001_bb0755","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.vaccine.2005.04.026","article-title":"The virosome concept for influenza vaccines","volume":"23","author":"Huckriede","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.01.001_bb0760","series-title":"Mymetics Starts Second Preclinical Study for Virosome-based Covid-19 Vaccine","author":"Kempers","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0765","series-title":"A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom","author":"Clinicaltrials_gov","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0770","series-title":"Novavax Initiates Efficacy Trial of COVID-19 Vaccine in South Africa","author":"Novavax","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0775","series-title":"COVID-19 Tracker: Warp Speed Chief Eyes Timeline for Pfizer, Moderna, AZ Shot Data; FDA can Reveal Safety info If Vaccine Makers Don't, Official Says, Fierce_Pharma","author":"Sagonowsky","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0780","series-title":"Dynavax Announces First Participants Dosed in Phase 1 Clinical Trial Evaluating Clover Biopharmaceuticals\u2019 COVID-19 S-Trimer Vaccine Candidate with CpG 1018 Adjuvant","author":"Biospace","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0785","series-title":"Clover Announces Formation of a Global Scientific Advisory Board for its COVID-19 Vaccine Program","author":"Clover_Biopharma","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0790","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.01.001_bb0795","article-title":"Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment","author":"Malladi","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2021.01.001_bb0800","article-title":"A vaccine displaying a trimeric influenza-a ha stem protein on capsid-like particles elicits potent and long-lasting protection in mice","volume":"8","author":"Thrane","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.addr.2021.01.001_bb0805","series-title":"COVID-19 cVLP Vaccine Demonstrated as Effective in Mice","author":"de Jongh","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0810","series-title":"ExpreS2ion Announces Successful Manufacturing of the cVLP COVID-19 Vaccine and Further Positive Updates","author":"Frandsen","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0815","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s12026-013-8468-x","article-title":"Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer and infectious diseases","volume":"57","author":"Strbo","year":"2013","journal-title":"Immunol. Res."},{"key":"10.1016\/j.addr.2021.01.001_bb0820","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jcpa.2014.01.004","article-title":"The pathology and pathogenesis of experimental severe acute respiratory syndrome and influenza in animal models","volume":"151","author":"van den Brand","year":"2014","journal-title":"J. Comp. Pathol."},{"key":"10.1016\/j.addr.2021.01.001_bb0825","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1128\/CVI.00455-14","article-title":"Multiple low-dose challenges in a rhesus macaque AIDS vaccine trial result in an evolving host response that affects protective outcome","volume":"21","author":"Selinger","year":"2014","journal-title":"Clin. Vaccine Immunol.: CVI"},{"key":"10.1016\/j.addr.2021.01.001_bb0830","article-title":"Induction of SARS-CoV-2 protein S-specific CD8+T cells in the lungs of gp96-Ig-S vaccinated mice","author":"Fisher","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.addr.2021.01.001_bb0835","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01083-20","article-title":"COVID-19 vaccines: \u201cWarp Speed\u201d needs mind melds, not warped minds","volume":"94","author":"Moore","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.01.001_bb0840","series-title":"Correlates and Disparities of COVID-19 Vaccine Hesitancy","author":"Callaghan","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0845","article-title":"Protein-based Covid-19 vaccines could overshadow rivals","author":"King","year":"2020","journal-title":"Chem. World"},{"key":"10.1016\/j.addr.2021.01.001_bb0850","series-title":"Pfizer, Moderna's Coronavirus Shot Rollouts Could Freeze Up, Experts Say, Citing Cold-storage Needs","author":"Blankenship","year":"2020"},{"key":"10.1016\/j.addr.2021.01.001_bb0855","article-title":"Safety and immunogenicity of heterologous and homologous two dose regimens of Ad26- and MVA-vectored ebola vaccines: a randomized, controlled phase 1 study","author":"Goldstein","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2021.01.001_bb0860","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines2030624","article-title":"Developments in viral vector-based vaccines","volume":"2","author":"Ura","year":"2014","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.addr.2021.01.001_bb0865","doi-asserted-by":"crossref","first-page":"11434","DOI":"10.1128\/JVI.78.20.11434-11438.2004","article-title":"Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors","volume":"78","author":"Casimiro","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.01.001_bb0870","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2021.01.001_bb0875","article-title":"Safety and immunogenicity of the Ad26.RSV.preF investigational vaccine coadministered with an influenza vaccine in older adults","author":"Sadoff","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2021.01.001_bb0880","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An Mrna vaccine against SARS-CoV-2 - preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.01.001_bb0885","article-title":"RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study","author":"Walsh","year":"2020","journal-title":"medRxiv: Preprint Server Health Sci."},{"key":"10.1016\/j.addr.2021.01.001_bb0890","series-title":"After Admitting Mistake, AstraZeneca Faces Difficult Questions About Its Vaccine","author":"Robbins","year":"2020"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X21000016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X21000016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T12:42:48Z","timestamp":1673440968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X21000016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":178,"alternative-id":["S0169409X21000016"],"URL":"http:\/\/dx.doi.org\/10.1016\/j.addr.2021.01.001","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":["Pharmaceutical Science"],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant protein vaccines, a proven approach against coronavirus pandemics","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2021.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}
Abstract
With the COVID-19 pandemic now ongoing for close to a year, people all over the world are still waiting for a vaccine to become available. The initial focus of accelerated global research and development efforts to bring a vaccine to market as soon as possible was on novel platform technologies that promised speed but had limited history in the clinic. In contrast, recombinant protein vaccines, with numerous examples in the clinic for many years, missed out on the early wave of investments from government and industry. Emerging data are now surfacing suggesting that recombinant protein vaccines indeed might offer an advantage or complement to the nucleic acid or viral vector vaccines that will likely reach the clinic faster. Here, we summarize the current public information on the nature and on the development status of recombinant subunit antigens and adjuvants targeting SARS-CoV-2 infections.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
